{\rtf1 \ansi 
{\colortbl;
\red0\green0\blue0;
\red255\green255\blue255;
\red255\green0\blue0;
\red0\green255\blue0;
\red0\green0\blue255;
\red0\green255\blue255;
\red255\green0\blue255;
\red255\green255\blue0;
\red0\green0\blue128;
\red0\green128\blue128;
\red0\green128\blue0;
\red128\green0\blue128;
\red128\green0\blue0;
\red128\green128\blue0;
\red128\green128\blue128;
\red192\green192\blue192;
\red170\green170\blue170;
\red85\green85\blue85;
\red14\green86\blue140;
\red37\green37\blue37;
\red33\green33\blue33;
\red119\green119\blue119;
\red238\green238\blue238;
\red20\green93\blue164;
\red246\green246\blue246;
\red255\green255\blue102;
\red80\green80\blue80;
\red51\green51\blue51;
\red181\green79\blue104;
\red204\green204\blue204;
\red151\green151\blue151;
\red21\green137\blue21;
\red255\green248\blue96;
\red106\green144\blue39;
\red254\green254\blue0;
\red56\green124\blue43;
\red0\green114\blue54;
\red112\green112\blue112;
\red247\green247\blue247;
\red107\green107\blue106;
\red232\green233\blue232;
\red249\green249\blue249;
\red223\green223\blue223;
\red239\green239\blue239;
\red236\green236\blue236;
\red187\green187\blue187;
\red255\green255\blue198;
\red249\green250\blue251;
\red228\green231\blue232;
\red214\green9\blue9;
\red255\green255\blue174;
\red190\green190\blue252;
\red233\green233\blue233;
\red240\green240\blue240;
\red105\green105\blue105;
\red227\green227\blue227;
\red61\green61\blue61;
\red218\green218\blue218;
\red214\green78\blue69;
\red61\green61\blue60;
\red250\green222\blue100;
\red183\green242\blue206;
\red255\green194\blue211;
\red255\green255\blue204;
\red255\green204\blue0;
\red118\green118\blue118;
\red255\green210\blue183;
\red182\green231\blue243;
\red203\green203\blue203;
\red245\green245\blue245;
\red229\green243\blue255;
\red179\green218\blue255;
\red153\green153\blue153;
\red71\green120\blue194;
\red240\green248\blue255;
\red127\green127\blue127;
\red204\green255\blue255;
\red120\green162\blue47;
\red251\green252\blue255;
\red72\green72\blue72;
\red190\green195\blue204;
\red208\green208\blue208;
\red239\green122\blue2;
\red214\green214\blue214;
\red102\green0\blue102;
\red185\green185\blue185;
\red188\green41\blue30;
\red190\green237\blue228;
\red243\green243\blue243;
\red24\green140\blue181;
\red89\green89\blue89;
\red86\green86\blue86;
\red16\green58\blue89;
\red255\green204\blue153;
\red23\green94\blue146;
\red172\green172\blue172;
\red9\green56\blue84;
}
{\fonttbl {
\f0 Arial;}{
\f1 Symbol;}{
\f2 Times New Roman;}{
\f3 georgia;}{
\f4 sans-serif;}{
\f5 Source Sans Pro;}{
\f6 serif;}{
\f7 Courier New;}{
\f8 Helvetica;}{
\f9 Knowledge;}
}
{\*\generator Apache XML Graphics RTF Library;}
\fet0 \ftnbj 
{\*\listtable
{\list\listtemplateid1761052014\listsimple{\listlevel\leveljc\levelfollow0\levelspace0\levelindent0{\leveltext\'01\u160\'3f}{\levelnumbers}}{\listname ;}\listid-2077063470}
}
{\*\listoverridetable
{\*\listoverride{\listid-2077063470\listoverridecount0\ls1}}
}
\paperw12240 \paperh15840 \margt1080 \margb1080 \margl1080 \margr1080 \headery720 \footery720 \itap0 \cols2 
\sectd {\header {
{\trowd \ltrrow \trleft0 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrl \trql \clvertalb \clwWidth9380 \cellx9380 
\clpadb60 \clpadfb3 \clpadl400 \clpadfl3 \clbrdrt \clbrdrb \brdrcf17 \brdrw20 \brdrs \clbrdrr \trql \clwWidth700 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
{\b1 \cf18 \f0 \i0 \fs18 
{\b1 \cf18 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Vanda Pharmaceuticals Inc. v. West-Ward Pharmaceuticals..., 887 F.3d 1117 (2018)
}
}
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 
}\qr \b0 \cf1 \f0 \ri0 \i0 \fs18 \li0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\b0 \cf1 \f0 \ri0 \i0 \ql \fs18 \li0 
{\b0 \cf1 \f0 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
126 U.S.P.Q.2d 1266
}
}\b0 \cf1 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs18 \li0 \sa0 \sb0 \intbl \cell \row }}\par }{\footer {
{\trowd \lastrow \trleft0 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrl \trql \clvertalb \clwWidth9300 \cellx9300 
\clpadl60 \clpadfl3 \clbrdrt \brdrcf17 \brdrw20 \brdrs \clbrdrb \clbrdrr \trql \clwWidth700 \cellx10000 
\intbl 
{\b0 \cf17 \f0 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 
}
{\*\shppict {\pict \pngblip \picw78 \pich10 \picwgoal1170 \pichgoal150 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}}
{\b0 \cf17 \f0 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
}
}\b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \ql \fs20 \li0 \sa0 \sb0 \intbl \cell \intbl 
{\qr \b0 \cf17 \f0 \ri0 \i0 \fs20 \li0 
{\b0 \i0 \ul0 \fs20 \f0 \chpgn }
}\qr \b0 \cf17 \f0 \ri0 \ul0 \strike0 \i0 \fs20 \li0 \intbl \cell \row }}\par }
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_document_15}{\*\bkmkend co_document_15}
{\b0 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart I7b55ac403f3c11e8a70fc9d8a0b2aef5_Target}{\*\bkmkend I7b55ac403f3c11e8a70fc9d8a0b2aef5_Target}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeKC_15}{\*\bkmkend co_readingModeKC_15}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeCitatorFlag_15}{\*\bkmkend co_readingModeCitatorFlag_15}
{\b0 \cf1 \f2 \i0 \fs16 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/RelatedInformation/Flag?documentGuid=I7b55ac403f3c11e8a70fc9d8a0b2aef5&transitionType=Document&originationContext=docHeaderFlag&Rank=0&rs=cblt1.0&vr=3.0&contextData=(sc.Search)" }{\fldrslt 
{\*\shppict {\pict \pngblip \picw16 \pich16 \picwgoal255 \pichgoal255 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}}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
KeyCite Yellow Flag - Negative Treatment
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\*\bkmkstart co_readingModeNegativeTreatment_15}{\*\bkmkend co_readingModeNegativeTreatment_15}
{\b0 \cf1 \f2 \i0 \fs16 {\fi-360 \li {\*\pn \pnlvlblt \ilvl0 \ls1 \pnindent0 \pnf1 {\f2 \pntxtb \u160\'3f}}{\listtext \b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 \u160\'3f\tab }\ls1 {\pntext }
{\pard }\b0 \cf1 \f2 \ri0 \i0 \qj \fs16 \li0 
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Distinguished by 
}
}
{\field {\*\fldinst HYPERLINK "https://www.westlaw.com/Document/If5800120c15111eabb269ba69a79554c/View/FullText.html?navigationPath=RelatedInfo%2Fv4%2Fkeycite%2Fnav%2F%3Fguid%3DIf5800120c15111eabb269ba69a79554c%26ss%3D2044320422%26ds%3D2051415079%26origDocGuid%3DI7b55ac403f3c11e8a70fc9d8a0b2aef5&listSource=RelatedInfo&list=NegativeCitingReferences&rank=0&ppcid=05f75ac914c54a8c852ba600a31f2ee4&originationContext=docHeader&transitionType=NegativeTreatment&contextData=%28sc.Search%29&VR=3.0&RS=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
In re Zunshine
}
{\b0 \cf19 \f2 \i0 \fs16 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
, 
}
}}}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
Fed.Cir., 
}
}
{\b0 \cf1 \f2 \i0 \fs16 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
July 8, 2020
\par {\pntext }
}
}
}
}
}
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
887 F.3d 1117
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
United States Court of Appeals, Federal Circuit.
\par 
}
}
}
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb240 
VANDA PHARMACEUTICALS INC., Plaintiff-Appellee
\par 
}
}
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5000067560)&saveJuris=False&contentType=BUSINESS-INVESTIGATOR&startIndex=1&contextData=(sc.Default)&categoryPageUrl=Home%2fCompanyInvestigator&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem" }{\fldrslt 
{\b0 \cf19 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
Aventisub LLC
}}}
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
, Plaintiff
\par 
}
}
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
v.
\par 
}
}
{\b0 \qc \cf20 \f3 \ri120 \i0 \fs24 \li120 
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Search/Results.html?query=advanced%3a+OAID(5059305620)&saveJuris=False&contentType=BUSINESS-INVESTIGATOR&startIndex=1&contextData=(sc.Default)&categoryPageUrl=Home%2fCompanyInvestigator&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem" }{\fldrslt 
{\b0 \cf19 \f3 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
West-Ward Pharmaceuticals Corp.
}}}
{\b0 \cf20 \f3 \ul0 \strike0 \i0 \fs24 \sa240 \sb0 
, Defendants-Appellants
\par 
}
}
}
}
{\b0 \qc \cf1 \f2 \ri0 \i0 \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
2016-2707, 2016-2708
\par 
}
}
}
{\b0 \cf1 \f3 \i0 \fs20 
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
|
\par 
}
}
{\b0 \qc \cf1 \f3 \ri0 \i0 \fs20 \li200 
{\b0 \cf1 \f3 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
Decided: April 13, 2018
\par 
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_synopsis_15}{\*\bkmkend co_synopsis_15}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
Synopsis
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Background:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Owner of patent related to a method of treating schizophrenia patients with iloperidone wherein the dosage range was based on the patient\rquote s genotype brought infringement action against manufacturer of generic drug. Following bench trial, the United States District Court for the District of Delaware, Nos. 1:13-cv-01973-GMS, 1:14-cv-00757-GMS, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0132747001&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Gregory M. Sleet
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, J., 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
203 F.Supp.3d 412
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, determined that patent claims were infringed and not invalid. Manufacturer appealed.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Holdings:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Court of Appeals, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0225327201&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Lourie
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
, Circuit Judge, held that:
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
district court had subject matter jurisdiction over patent infringement suit;
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
patent owner established that if proposed product were marketed, it would infringe patent;
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
claims were directed to patent eligible subject matter; and
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
claims were not invalid for lack of adequate written description.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Affirmed.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0324402101&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Prost
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Chief Judge, filed a dissenting opinion.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1120_15}{\*\bkmkend co_pp_sp_506_1120_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1120
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Appeals from the United States District Court for the District of Delaware in Nos. 1:13-cv-01973-GMS, 1:14-cv-00757-GMS, Judge 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0132747001&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Gregory M. Sleet
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_attorneysAndLawFirms_15}{\*\bkmkend co_attorneysAndLawFirms_15}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
Attorneys and Law Firms
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0142351601&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Nicholas P. Groombridge
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Paul, Weiss, Rifkind, Wharton & Garrison LLP, New York, NY, argued for plaintiff-appellee. Also represented by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0384392301&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Kira A. Davis
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0498677299&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Daniel Klein
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0330769501&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Eric Alan Stone
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0426581101&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Josephine Young
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0108551301&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Kenneth G. Schuler
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Latham & Watkins LLP, Chicago, IL, argued for defendants-appellants. Also represented by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0189595701&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Daniel Brown
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, New York, NY; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0426877301&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Robert J. Gajarsa
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Washington, DC.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Before 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0324402101&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Prost
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Chief Judge, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0225327201&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Lourie
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0211865201&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Hughes
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, Circuit Judges.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_opinion_15}{\*\bkmkend co_opinion_15}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
Opinion
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ic700776348c011ecb4b0a4d54f706}{\*\bkmkend co_anchor_Ic700776348c011ecb4b0a4d54f706}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Dissenting opinion filed by Chief Judge 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0324402101&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Prost
}}}
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb600 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0225327201&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Lourie
}}}
\sa200 
\sb200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
, Circuit Judge.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ic722cc7248c011ecb4b0a4d54f706}{\*\bkmkend co_anchor_Ic722cc7248c011ecb4b0a4d54f706}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
West-Ward Pharmaceuticals International Limited and West-Ward Pharmaceuticals Corp. (collectively, \u8220\'3fWest-Ward\u8221\'3f) appeal from the decision of the United States District Court for the District of Delaware holding, after a bench trial, claims 1\u8211\'3f9, 11\u8211\'3f13, and 16 (\u8220\'3fthe asserted claims\u8221\'3f) of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent 8,586,610 (\u8220\'3fthe \lquote 610 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 infringed and not invalid. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Vanda Pharm. Inc. v. Roxane Labs., Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 203 F.Supp.3d 412 (D. Del. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Opinion
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f). For the following reasons, we affirm.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ic72368b148c011ecb4b0a4d54f706}{\*\bkmkend co_anchor_Ic72368b148c011ecb4b0a4d54f706}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Background
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
I.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Aventisub LLC (\u8220\'3fAventisub\u8221\'3f) owns and Vanda Pharmaceuticals Inc. (\u8220\'3fVanda\u8221\'3f and collectively, with Aventisub, \u8220\'3fPlaintiffs\u8221\'3f) holds an exclusive worldwide license to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Reissue Patent 39,198 (\u8220\'3fthe \lquote 198 patent\u8221\'3f)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 expired on November 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1121_15}{\*\bkmkend co_pp_sp_506_1121_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1121
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 15, 2016.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00012044320422_ID0EKDAI_15}{\*\bkmkend co_fnRef_B00012044320422_ID0EKDAI_15}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00012044320422_15" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Vanda also owns the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which will expire on November 2, 2027.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 relates to a method of treating 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 patients with iloperidone wherein the dosage range is based on the patient\rquote s genotype. The cytochrome P450 2D6 gene (\u8220\'3fCYP2D6\u8221\'3f) encodes an enzyme known to metabolize a large number of drugs, including iloperidone. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 1 ll. 29\u8211\'3f36. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 teaches \u8220\'3fthat treatment of a patient, who has lower CYP2D6 activity than a normal person, with a drug[, such as iloperidone,] that is pre-disposed to cause QT
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00022044320422_ID0ETGAI_15}{\*\bkmkend co_fnRef_B00022044320422_ID0ETGAI_15}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00022044320422_15" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
2
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 prolongation and is metabolized by the CYP2D6 enzyme, can be accomplish[ed] more safely by administering a lower dose of the drug than would be administered to a person who has normal CYP2D6 enzyme activity.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 2 ll. 15\u8211\'3f21. QT prolongation can lead to serious cardiac problems. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 refers to patients who have lower than normal CYP2D6 activity as CYP2D6 poor metabolizers. It provides examples of dose reductions for poor metabolizers compared to the dose given to someone with a wildtype genotype. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 9 ll. 34\u8211\'3f47, col. 11 ll. 22\u8211\'3f28.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is representative and reads as follows:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A method for treating a patient with iloperidone, wherein the patient is suffering from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, the method comprising the steps of:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
determining whether the patient is a CYP2D6 poor metabolizer by:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
obtaining or having obtained a biological sample from the patient;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
performing or having performed a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 assay on the biological sample to determine if the patient has a CYP2D6 poor metabolizer genotype; and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
if the patient has a CYP2D6 poor metabolizer genotype, then internally administering iloperidone to the patient in an amount of 12 mg/day or less, and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
if the patient does not have a CYP2D6 poor metabolizer genotype, then internally administering iloperidone to the patient in an amount that is greater than 12 mg/day, up to 24 mg/day,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
wherein a risk of QTc prolongation for a patient having a CYP2D6 poor metabolizer genotype is lower following the internal administration of 12 mg/day or less than it would be if the iloperidone were administered in an amount of greater than 12 mg/day, up to 24 mg/day.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 17 ll. 2\u8211\'3f25.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Vanda owns New Drug Application (\u8220\'3fNDA\u8221\'3f) 22-192 for Fanapt\u174\'3f (iloperidone), an atypical antipsychotic approved by the U.S. Food and Drug Administration (\u8220\'3fFDA\u8221\'3f) in 2009 under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for the treatment of patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Vanda was able to obtain FDA approval for iloperidone based, at least in part, on the invention disclosed in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which reduces the side effects associated with QTc prolongation, enabling safer treatment of patients with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are listed in connection with Fanapt\u174\'3f in the FDA\rquote s 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Approved Drug Products with Therapeutic Equivalence Evaluations
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, commonly known as the \u8220\'3fOrange Book.\u8221\'3f
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ic7284ab148c011ecb4b0a4d54f706}{\*\bkmkend co_anchor_Ic7284ab148c011ecb4b0a4d54f706}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1122_15}{\*\bkmkend co_pp_sp_506_1122_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1122
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
 II.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 2013, West-Ward
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00032044320422_ID0E6OAI_15}{\*\bkmkend co_fnRef_B00032044320422_ID0E6OAI_15}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00032044320422_15" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
3
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 filed Abbreviated New Drug Application (\u8220\'3fANDA\u8221\'3f) 20-5480 seeking approval to commercially manufacture, use, offer to sell, and sell a generic version of Fanapt\u174\'3f in 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg strengths for the treatment of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_267600008f864" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(j)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. At that time, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 had not yet issued and only the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was listed in the Orange Book. The ANDA contained a certification per 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_0123000089ab5" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(j)(2)(A)(vii)(IV)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fParagraph IV certification\u8221\'3f) that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was invalid and/or would not be infringed by West-Ward. West-Ward then sent the notice required by 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_979c0000b55d2" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(j)(2)(B)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fParagraph IV notice\u8221\'3f) of its Paragraph IV certification. On November 25, 2013, Plaintiffs filed Civil Action No. 13-1973 (\u8220\'3f2013 suit\u8221\'3f) in the U.S. District Court for the District of Delaware (\u8220\'3fdistrict court\u8221\'3f) alleging infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 198 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The proposed ANDA label is substantially identical in all material respects to the Fanapt\u174\'3f label. The proposed label states that: iloperidone is \u8220\'3findicated for the treatment of adults with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,\u8221\'3f J.A. 15104 \u167\'3f 1; \u8220\'3f[t]he recommended target dosage of iloperidone tablets is 12 to 24 mg/day,\u8221\'3f J.A. 15103; \u8220\'3f[t]he recommended starting dose for iloperidone tablets is 1 mg twice daily,\u8221\'3f J.A. 15105 \u167\'3f 2.1; and \u8220\'3f[i]loperidone must be titrated slowly from a low starting dose,\u8221\'3f J.A. 15105 \u167\'3f 2.1. The proposed label provides that the \u8220\'3f[i]loperidone dose should be reduced by one-half for poor metabolizers of CYP2D6 [
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see Pharmacokinetics (12.3)
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ].\u8221\'3f J.A. 15105 \u167\'3f 2.2. Section 5.2, entitled \u8220\'3fQT Prolongation,\u8221\'3f explains: \u8220\'3filoperidone was associated with QTc prolongation of 9 msec at an iloperidone dose of 12 mg twice daily\u8221\'3f and that \u8220\'3f[c]aution is warranted when prescribing iloperidone ... in patients with reduced activity of CYP2D6 [
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see
}
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Clinical Pharmacology (12.3)
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ].\u8221\'3f J.A. 5106\u8211\'3f07 \u167\'3f 5.2.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ic72a468148c011ecb4b0a4d54f706}{\*\bkmkend co_anchor_Ic72a468148c011ecb4b0a4d54f706}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
III.
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Meanwhile, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 issued on November 19, 2013, and on June 16, 2014, Vanda filed Civil Action No. 14-757 (\u8220\'3f2014 suit\u8221\'3f) in the district court alleging infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. On January 15, 2015, Vanda listed the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in the Orange Book for Fanapt\u174\'3f. On May 6, 2015, West-Ward sent Vanda a Paragraph IV notice with respect to the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 notifying Vanda that it amended ANDA 20-5480 to contain a Paragraph IV certification that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is invalid and/or not infringed. J.A. 19696; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_0123000089ab5" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(j)(2)(B)(ii)(II)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The district court consolidated the 2013 and 2014 suits.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Following a bench trial, the district court found that West-Ward\rquote s proposed products induce infringement of the asserted claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, but do not contributorily infringe them. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_7903_435&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_435" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Opinion
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 203 F.Supp.3d at 435
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The court held that West-Ward\rquote s \u8220\'3fsubmission of a paragraph IV certification for the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 [p]atent is an act of infringement\u8221\'3f and that Vanda\rquote s expert Dr. Alva \u8220\'3fpracticed the steps of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 [p]atent claims\u8221\'3f with Fanapt\u174\'3f. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_7903_433&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_433" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 433
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The court found that the proposed ANDA label \u8220\'3frecommends\u8221\'3f: (1) \u8220\'3fpractitioners use iloperidone to treat patients suffering from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f; (2) \u8220\'3foral administration of iloperidone tablets at 12 to 24 mg/day to non-genotypic CYP2D6 poor metabolizers and 12 mg/day or less to genotypic CYP2D6 poor metabolizers\u8221\'3f; and (3) \u8220\'3fpractitioners perform or have performed 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1123_15}{\*\bkmkend co_pp_sp_506_1123_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1123
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 assay to determine whether patients are CYP2D6 poor metabolizers.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_7903_432&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_432" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 432
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (first citing J.A. 15104\u8211\'3f05 \u167\'3f\u167\'3f 1, 2.1, 2.2; then citing J.A. 15120\u8211\'3f21 \u167\'3f 12.3).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The district court also held that the asserted claims were not invalid under 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u167\'3f 103, or \u167\'3f 112 for lack of written description. The court did conclude that \u8220\'3fthe asserted claims depend upon laws of nature,\u8221\'3f specifically, \u8220\'3fthe relationship between iloperidone, CYP2D6 metabolism, and QTc prolongation.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_7903_428&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_428" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 428\u8211\'3f29
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. But the court explained that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3faddresses natural relationships to which the claims add conducting CYP2D6 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 tests to determine the appropriate dose of iloperidone to reduce QTc-related risks.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_7903_429&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_429" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 429
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fThe court f[ound] that while it may have been conventional to investigate for side-effects, [West-Ward] has not proven by clear and convincing evidence that the precise test and the discovered results were routine or conventional.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The court found that the data disclosed in the patent were \u8220\'3fsufficient to support possession of the claimed dosage range, even if not statistically significant.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_7903_431&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_431" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 431
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The court determined that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_f4aa000038542" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(4)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 relief was unavailable for the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because it did not issue until after the ANDA was filed.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00042044320422_ID0EUBBI_15}{\*\bkmkend co_fnRef_B00042044320422_ID0EUBBI_15}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00042044320422_15" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
4
}}}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_7903_435&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_435" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 435
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The court determined that injunctive relief was appropriate, however, pursuant to its \u8220\'3fgeneral equitable power.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The court enjoined West-Ward from engaging in the commercial manufacture, use, offer to sell, sale in or importation into the United States of West-Ward\rquote s ANDA product prior the expiration of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The court further ordered that \u8220\'3f[t]he effective date of any [FDA] approval of [West-Ward\rquote s] ANDA No. 20-5480 shall be a date not earlier than the latest of the expiration of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 [p]atent or any applicable exclusivities and extensions.\u8221\'3f J.A. 33
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
West-Ward timely appealed from the district court\rquote s final judgment. We have jurisdiction under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1295&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_7b9b000044381" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
28 U.S.C. \u167\'3f 1295(a)(1)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ic72f288148c011ecb4b0a4d54f706}{\*\bkmkend co_anchor_Ic72f288148c011ecb4b0a4d54f706}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Discussion
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B12044320422_15}{\*\bkmkend co_anchor_B12044320422_15}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B22044320422_15}{\*\bkmkend co_anchor_B22044320422_15}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
On appeal from a bench trial, we review a district court\rquote s conclusions of law 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
de novo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and its findings of fact for clear error. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004340643&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1058&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1058" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Golden Blount, Inc. v. Robert H. Peterson Co.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 365 F.3d 1054, 1058 (Fed. Cir. 2004)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. A factual finding is only clearly erroneous if, despite some supporting evidence, we are left with the definite and firm conviction that a mistake has been made. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1948119024&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_395&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_395" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
United States v. U.S. Gypsum Co.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 333 U.S. 364, 395, 68 S.Ct. 525, 92 L.Ed. 746 (1948)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1986121975&pubNum=0000350&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_350_1559&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_1559" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Polaroid Corp. v. Eastman Kodak Co.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 789 F.2d 1556, 1559 (Fed. Cir. 1986)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe burden of overcoming the district court\rquote s factual findings is, as it should be, a heavy one.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ic72febd148c011ecb4b0a4d54f706}{\*\bkmkend co_anchor_Ic72febd148c011ecb4b0a4d54f706}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
I. Jurisdiction
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B32044320422_15}{\*\bkmkend co_anchor_B32044320422_15}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We must first address whether the district court properly exercised jurisdiction over the 2014 suit. On November 16, 2017, we directed supplemental briefing on jurisdiction. Both parties responded with supplemental briefing, which, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
inter alia
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, addressed whether there is district court jurisdiction under the Drug Price Competition and Patent Term Restoration Act of 1984 (\u8220\'3fthe Hatch-Waxman Act\u8221\'3f), 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1124_15}{\*\bkmkend co_pp_sp_506_1124_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1124
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=l&pubNum=1077005&cite=UUID(IE18BBC5D63-B24B84B86B5-560A5141A87)&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=SL&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pub. L. No. 98-417, 98 Stat. 1585 (1984)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 over an action in which the asserted patent issued after the ANDA was filed and the complaint was filed before the ANDA applicant submitted a Paragraph IV certification for the asserted patent.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Vanda argues that its allegations of infringement under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 created subject matter jurisdiction in the district court under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1331&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
28 U.S.C. \u167\'3f 1331
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1338&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_8b3b0000958a4" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 1338(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and presented a justiciable controversy. Vanda further argues that the Declaratory Judgment Act, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS2201&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
28 U.S.C. \u167\'3f 2201
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, provides an alternative basis for jurisdiction because it alleged that West-Ward would infringe the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_8b3b0000958a4" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_4b24000003ba5" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 by selling iloperidone.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
West-Ward argues that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does not create a basis for subject matter jurisdiction over Vanda\rquote s infringement claims. West-Ward contends that a claim for 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 infringement can only be based on patents that have issued before an ANDA is filed. Moreover, West-Ward argues, even if the amended Paragraph IV certification could qualify as an act of infringement under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, jurisdiction would still be lacking because the certification was not made before the 2014 suit was filed. West-Ward further argues that there is declaratory judgment jurisdiction over its claims for relief, but not over Vanda\rquote s claims for infringement.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We agree with Vanda that the district court had jurisdiction over this case. We have previously explained that:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
By enacting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, Congress thus established a specialized new cause of action for patent infringement. When patentees pursue this route, their claims necessarily arise under an Act of Congress relating to patents. In short, \u8220\'3f[o]nce Congress creates an act of infringement, jurisdiction in the district courts is proper under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1338&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_8b3b0000958a4" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
28 U.S.C. \u167\'3f 1338(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.\u8221\'3f
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027068440&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1377&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1377" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
AstraZeneca Pharm. LP v. Apotex Corp.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (
}
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
AstraZeneca II
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ), 669 F.3d 1370, 1377 (Fed. Cir. 2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (alteration in original) (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2003243620&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1330&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1330" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Allergan, Inc. v. Alcon Labs., Inc.,
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 324 F.3d 1322, 1330 (Fed. Cir. 2003)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). The Supreme Court has similarly explained that \u8220\'3fthe federal courts have jurisdiction over [a suit alleging infringement under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ] for a single, simple reason: It \u8216\'3far[ose] under a[n] Act of Congress relating to patents.\u8217\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027504856&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_412&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_412" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Caraco Pharm. Labs., Ltd. v. Novo Nordisk A/S
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (
}
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Caraco II
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ), 566 U.S. 399, 412 n.5, 132 S.Ct. 1670, 182 L.Ed.2d 678 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (second and third alterations in original) (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1338&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_8b3b0000958a4" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
28 U.S.C. \u167\'3f 1338(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Here, Vanda\rquote s complaint alleged that West-Ward infringed the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 by filing the ANDA. J.A. 10002. Nothing more was required to establish the district court\rquote s subject matter jurisdiction pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1338&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_8b3b0000958a4" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
28 U.S.C. \u167\'3f 1338(a)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027068440&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1377&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1377" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
AstraZeneca II
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 669 F.3d at 1377
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (explaining that \u8220\'3fthe requirements for jurisdiction in the district courts are met once a patent owner alleges that another\rquote s filing of an ANDA infringes its patent under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and this threshold jurisdictional determination does not depend on the ultimate merits of the claims\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
West-Ward\rquote s arguments relating to whether there was a qualifying act of infringement raise potential merits problems, not jurisdictional issues. We have previously rejected the argument that a court\rquote s jurisdiction \u8220\'3fhinged on whether [plaintiff] asserted a \u8216\'3fvalid\u8217\'3f claim under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027068440&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The Supreme Court has similarly explained that \u8220\'3f[t]he want of an infringing act [under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ] is a merits problem, not a jurisdictional one.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027504856&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_708_412&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_412" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Caraco II
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 412 n.5, 132 S.Ct. 1670
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Thus, whether Vanda alleged, and subsequently 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1125_15}{\*\bkmkend co_pp_sp_506_1125_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1125
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 proved, an infringing act is a merits question, not a jurisdictional one.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B42044320422_15}{\*\bkmkend co_anchor_B42044320422_15}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moreover, an actual controversy has existed between the parties from the time when the suit was commenced. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2011826376&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1339&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1339" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Teva Pharm. USA, Inc. v. Novartis Pharm. Corp.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 482 F.3d 1330, 1339\u8211\'3f45 (Fed. Cir. 2007)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (reversing district court\rquote s conclusion that it lacked jurisdiction because there was no justiciable controversy between the ANDA applicant and NDA holder where there was a prior suit between the parties involving a different patent to which the ANDA applicant had submitted a Paragraph IV certification). \u8220\'3fTo qualify as a case fit for federal-court adjudication, \u8216\'3fan actual controversy must be extant at all stages of review,\u8217\'3f \u8221\'3f including \u8220\'3f \u8216\'3fat the time the complaint is filed.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997060684&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_67&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_67" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Arizonans for Official English v. Arizona
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 520 U.S. 43, 67, 117 S.Ct. 1055, 137 L.Ed.2d 170 (1997)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1975129828&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_401&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_401" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Preiser v. Newkirk
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 422 U.S. 395, 401, 95 S.Ct. 2330, 45 L.Ed.2d 272 (1975)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). Here, West-Ward had filed an ANDA and Vanda had sued it. The mere fact that West-Ward had not submitted a Paragraph IV certification for the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 until after Vanda filed suit does not establish that there was not a justiciable controversy over which the court could exercise jurisdiction. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997083946&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1569&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1569" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Glaxo, Inc. v. Novopharm, Ltd.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 110 F.3d 1562, 1569 (Fed. Cir. 1997)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3f[
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section] 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 provide[s] patentees with a defined act of infringement sufficient to create case or controversy jurisdiction to enable a court to promptly resolve any dispute concerning infringement and validity.\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1995163589&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1401&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1401" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
DuPont Merck Pharm. Co. v. Bristol-Myers Squibb Co.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 62 F.3d 1397, 1401 (Fed. Cir. 1995)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (reversing a district court\rquote s determination in declaratory judgment action \u8220\'3fthat an actual controversy would only occur upon [ANDA applicants\rquote ] filing of paragraph IV certifications\u8221\'3f).
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00052044320422_ID0EW4BI_15}{\*\bkmkend co_fnRef_B00052044320422_ID0EW4BI_15}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00052044320422_15" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
5
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Thus, the district court properly had jurisdiction over the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 under the Hatch-Waxman Act.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ic7367b8248c011ecb4b0a4d54f706}{\*\bkmkend co_anchor_Ic7367b8248c011ecb4b0a4d54f706}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
II. Infringement
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B52044320422_15}{\*\bkmkend co_anchor_B52044320422_15}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B62044320422_15}{\*\bkmkend co_anchor_B62044320422_15}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B72044320422_15}{\*\bkmkend co_anchor_B72044320422_15}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In a bench trial, infringement is a question of fact that we review for clear error. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2010230679&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1289&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1289" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alza Corp. v. Mylan Labs., Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 464 F.3d 1286, 1289 (Fed. Cir. 2006)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. An infringement inquiry pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3fis focused on a comparison of the asserted patent [claims] against 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote the product that is likely to be sold following ANDA approval.\rquote \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032909107&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1186&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1186" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alcon Research Ltd. v. Barr Labs., Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 745 F.3d 1180, 1186 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002504341&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1373&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1373" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Abbott Labs. v. TorPharm, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 300 F.3d 1367, 1373 (Fed. Cir. 2002)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). The patentee bears the burden of proving infringement by a preponderance of the evidence. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2003082816&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1366&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1366" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Warner\u8211\'3fLambert Co. v. Apotex Corp.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 316 F.3d 1348, 1366 (Fed. Cir. 2003)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ic7378cf148c011ecb4b0a4d54f706}{\*\bkmkend co_anchor_Ic7378cf148c011ecb4b0a4d54f706}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
A. The Applicability of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)(A)
}}}
\sa200 
\sb400 
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B82044320422_15}{\*\bkmkend co_anchor_B82044320422_15}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We first address whether, beyond the jurisdictional question, a claim for infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 can lie where the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 issued after the original ANDA was submitted and Vanda sued West-Ward for infringement of the asserted claims prior to West-Ward submitting a Paragraph IV certification. The district court held that West-Ward\rquote s submission of the Paragraph IV certification for the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was an act of infringement. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_7903_433&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_433" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Opinion
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 203 F.Supp.3d at 433
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. We review the district court\rquote s statutory interpretation without deference. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2003082816&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1355" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Warner\u8211\'3fLambert
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 316 F.3d at 1355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1126_15}{\*\bkmkend co_pp_sp_506_1126_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1126
}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B92044320422_15}{\*\bkmkend co_anchor_B92044320422_15}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Vanda argues that it proved an act of infringement under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. According to Vanda, \u8220\'3f[w]here a patent issues after an ANDA is filed but before FDA approval, and where\u8212\'3fas here\u8212\'3fthe applicant submits a Paragraph IV certification directed at the new patent, that amendment of the ANDA is an act of infringement under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f Appellee Br. 60.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
West-Ward responds that there can be no infringement under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because the ANDA was filed before the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 issued. West-Ward contends that the statutorily defined act of infringement excludes amendments to an ANDA and \u8220\'3fonly reaches ANDAs submitted \u8216\'3ffor a drug claim
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
ed
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in a 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
patent
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or the use of which is claim
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
ed
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in a 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
patent
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8217\'3f\u8212\'3fnot a drug that might or might not later be claimed in a patent or one that has been claimed in a provisional patent application or a patent-pending.\u8221\'3f Reply Br. 33 (emphases in original) (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ) (other internal quotation marks omitted).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Hatch-Waxman Act amended the Federal Food, Drug, and Cosmetic Act and the patent laws to enable generic drugs to be more easily approved and to respond to loss of effective patent life resulting from the requirement that drug products require premarket testing and then must undergo FDA review, actions that consume significant portions of a patent term. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1990094366&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_669&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_669" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Eli Lilly & Co. v. Medtronic, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 496 U.S. 661, 669\u8211\'3f70, 110 S.Ct. 2683, 110 L.Ed.2d 605 (1990)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Hatch-Waxman Act \u8220\'3fstr[ikes] a balance between two competing policy interests: (1) inducing pioneering research and development of new drugs and (2) enabling competitors to bring low-cost, generic copies of those drugs to market.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002075387&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1371&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1371" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Andrx Pharm., Inc. v. Biovail Corp.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 276 F.3d 1368, 1371 (Fed. Cir. 2002)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section 202 of the Act, codified at 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, created an \u8220\'3fartificial\u8221\'3f act of infringement. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1990094366&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_678&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_678" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Eli Lilly
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 496 U.S. at 678, 110 S.Ct. 2683
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. That provision provides in relevant part:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
It shall be 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
an act of infringement
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to submit ... 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
an application
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 under section 505(j) of the Federal Food, Drug, and Cosmetic Act[, codified at 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_267600008f864" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(j)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
,] ... 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
for a drug
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claimed in a patent or 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
the use of which is claimed in a patent
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, ... if the purpose of such submission is to obtain approval under such Act to engage in the commercial manufacture, use, or sale of a drug ... claimed in a patent or the use of which is claimed in a patent before the expiration of such patent.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphases added).
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 It \u8220\'3ffacilitates the early resolution of patent disputes between generic and pioneering drug companies by providing that the mere act of filing a Paragraph IV ANDA constitutes an act of patent infringement.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2015647167&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1283&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1283" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Caraco Pharm. Labs., Ltd. v. Forest Labs., Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (
}
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Caraco I
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ), 527 F.3d 1278, 1283 (Fed. Cir. 2008)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Litigation does not have to be delayed until actual sale of an accused product.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Although we agree with West-Ward that only an issued patent can give rise to a valid infringement claim under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, we disagree that that conclusion precludes Vanda\rquote s infringement claim in this case. The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is a patent \u8220\'3ffor a drug ... the use of which is claimed in a patent,\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, as contemplated in the Act even though it issued after West-Ward filed its ANDA. West-Ward subsequently amended its ANDA to include a Paragraph IV certification for the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 after it issued. The infringement analysis under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3frequire[s] consideration of the amended ANDA.\u8221\'3f 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1127_15}{\*\bkmkend co_pp_sp_506_1127_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1127
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034181282&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1390&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1390" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ferring B.V. v. Watson Labs., Inc.-Fla.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 764 F.3d 1382, 1390 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. \u8220\'3fThere is no support for the proposition that the question of infringement must be addressed solely based on the initial ANDA filing, given that the statute contemplates that the ANDA will be amended as a matter of course.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034181282&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Thus, amendments to an ANDA, including a Paragraph IV certification for a later-issued patent, can constitute an act of infringement under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1995220011&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1135&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1135" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bristol-Myers Squibb Co. v. Royce Labs., Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 69 F.3d 1130, 1135 (Fed. Cir. 1995)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (holding that by amending an ANDA to include a Paragraph IV certification, the applicant \u8220\'3fcommitted an act of infringement under the Hatch-Waxman Act because it sought \u8216\'3fto obtain approval ... to engage in the commercial manufacture, use, or sale of a drug ... claimed in a patent ... before the expiration of such patent\u8217\'3f \u8221\'3f (alternations in original) (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ) ).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B102044320422_15}{\*\bkmkend co_anchor_B102044320422_15}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Here, it is undisputed that West-Ward amended the ANDA by submitting a Paragraph IV certification regarding the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 after that patent issued. J.A. 19696; J.A. 6414\u8211\'3f15; Appellant Br. 10; Appellee Br. 59. Such an act is a qualifying act of infringement under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00062044320422_ID0EKWCI_15}{\*\bkmkend co_fnRef_B00062044320422_ID0EKWCI_15}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00062044320422_15" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
6
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 A filer of an ANDA is therefore subject to a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 infringement claim on a patent that issues after the filing of the ANDA, but before FDA approval. The resolution of infringement claims under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for patents that issue after an ANDA is submitted, but before it is approved, \u8220\'3ffacilitates the early resolution of patent disputes between generic and pioneering drug companies\u8221\'3f in accordance with the purpose of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2015647167&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1283&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1283" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Caraco I
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 527 F.3d at 1283
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The FDA regulatory framework and the legislative history further demonstrate that West-Ward is incorrect in asserting that \u8220\'3fapplication\u8221\'3f in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 excludes amendments to the ANDA. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Sections
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 102 of the Hatch-Waxman Act amended the Federal Food, Drug, and Cosmetics Act to create an abbreviated regulatory pathway for approval of generic drugs, codified at 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_267600008f864" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(j)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and to require NDA applicants to file certain patent information with the FDA, codified at 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_3fed000053a85" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(b)(1)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_fcf30000ea9c4" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(c)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. NDA holders have a continuing obligation to amend the NDA to include the same patent information for patents that issue after the NDA is approved. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_fcf30000ea9c4" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(c)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The FDA lists this patent information in the Orange Book.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
ANDA applications must contain one of four certifications for patents 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8220\'3ffor which information is required to be filed under [
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_4b24000003ba5" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ]\u8221\'3f: (1) \u8220\'3fthat such patent information has not been filed;\u8221\'3f (2) \u8220\'3fthat such patent has expired;\u8221\'3f (3) \u8220\'3fthe date on which such patent will expire;\u8221\'3f and (4) \u8220\'3fthat such patent is invalid or will not be infringed by the manufacture, use, or sale of the new drug for which the application is submitted.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_77230000858d4" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(j)(2)(A)(vii)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. If the ANDA applicant makes a Paragraph IV certification, it must provide notice to the NDA holder of the certification. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_979c0000b55d2" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u167\'3f 355(j)(2)(B)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Prior to FDA approval, ANDA applicants generally must amend or supplement ANDAs to submit an appropriate patent certification for patents that issue after submission of 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1128_15}{\*\bkmkend co_pp_sp_506_1128_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1128
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the ANDA. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_0123000089ab5" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u167\'3f 355(j)(2)(B)(ii)(II)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000547&cite=21CFRS314.94&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_0123000089ab5" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 C.F.R. \u167\'3f 314.94(a)(12)(viii)(C)(ii)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Thus, the regulatory framework expressly contemplates certifications for patents that issue after the ANDA is filed.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The type of certification under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_77230000858d4" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(j)(2)(A)(vii)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 impacts when FDA approval may be made effective. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9fbc0000bd582" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(j)(5)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. If an ANDA applicant submits a Paragraph IV certification, the statute provides for a thirty-month stay of effective FDA approval that may be shortened or lengthened in certain circumstances. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_83fb0000a4d76" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u167\'3f 355(j)(5)(B)(iii)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Congressional amendment of the thirty-month stay provision since the enactment of the Hatch-Waxman Act further supports the conclusion that \u8220\'3fapplication\u8221\'3f in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 includes amendments to the ANDA.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
As originally enacted, the Hatch-Waxman Act provided for a thirty-month stay as long as the suit was brought within 45 days of receipt of the Paragraph IV notice. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Hatch-Waxman Act, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=l&pubNum=1077005&cite=UUID(IE18BBC5D63-B24B84B86B5-560A5141A87)&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=SL&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pub. L. 98\u8211\'3f417
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 98 Stat. at 1589. Multiple thirty-month stays could therefore be triggered for the same ANDA as a consequence of the ANDA applicant submitting Paragraph IV certifications and notices for patents listed in the Orange Book that issued both before and after the submission of the original ANDA application. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002075387&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1378&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1378" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Andrx
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 276 F.3d at 1378
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (noting that FDA \u8220\'3ftreated the listing in the Orange Book of [a patent that issued after the ANDA was submitted] as requiring a new thirty-month stay of its approval of Andrx\rquote s ANDA\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In 2003, Congress amended 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_267600008f864" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(j)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to eliminate the possibility of multiple thirty-month stays for the same ANDA. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (\u8220\'3fthe MMA\u8221\'3f), 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=l&pubNum=1077005&cite=UUID(IAD8DA5DB03-D4438C99E4B-5B321B98D02)&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=SL&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pub. L. 108-173, \u167\'3f 1101, 117 Stat. 2066
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 2449 (2003); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=0364206349&pubNum=0100015&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=TV&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
H.R. Conf. Rep. No. 108-391, at 835\u8211\'3f36
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (2003), 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
reprinted in
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 2003 U.S.C.C.A.N. 1808, 2187. The MMA changed the requirements to obtain a thirty-month stay to add that the patent information for the patent to which the Paragraph IV certification is directed must have been submitted to the FDA \u8220\'3fbefore the date on which the [ANDA] 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
application (excluding an amendment or supplement to the application)
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ... was submitted.\u8221\'3f MMA, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=l&pubNum=1077005&cite=UUID(IAD8DA5DB03-D4438C99E4B-5B321B98D02)&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=SL&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Pub. L. 108-173
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u167\'3f 1101(a)(2), 117 Stat. at 2449 (emphasis added) (codified at 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_83fb0000a4d76" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(j)(5)(B)(iii)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). The MMA did not contain a corresponding amendment to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to exclude amendments and supplements to the ANDA as cognizable acts of infringement even though it amended 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_7fdd00001ca15" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 in other ways. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u167\'3f 1101(d), 117 Stat. at 2457. This history thus further supports the conclusion that \u8220\'3fapplication\u8221\'3f in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 includes amendments to the ANDA. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2019144488&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_174&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_174" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Gross v. FBL Fin. Servs., Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 557 U.S. 167, 174, 129 S.Ct. 2343, 174 L.Ed.2d 119 (2009)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fWhen Congress amends one statutory provision but not another, it is presumed to have acted intentionally.\u8221\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Thus, the district court properly conducted its infringement analysis for the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ic7434cc148c011ecb4b0a4d54f706}{\*\bkmkend co_anchor_Ic7434cc148c011ecb4b0a4d54f706}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
B. Inducement
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00072044320422_ID0ETIDI_15}{\*\bkmkend co_fnRef_B00072044320422_ID0ETIDI_15}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00072044320422_15" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
7
}}}
\sa200 
\sb400 
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B112044320422_15}{\*\bkmkend co_anchor_B112044320422_15}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We now turn to the merits of the infringement finding. West-Ward argues that the district court clearly erred in finding that it would induce infringement because Vanda failed to prove the requisite direct infringement and specific intent to induce infringement. Vanda responds that the district court correctly found that 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1129_15}{\*\bkmkend co_pp_sp_506_1129_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1129
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 West-Ward will induce infringement of the asserted claims.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B122044320422_15}{\*\bkmkend co_anchor_B122044320422_15}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B132044320422_15}{\*\bkmkend co_anchor_B132044320422_15}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B142044320422_15}{\*\bkmkend co_anchor_B142044320422_15}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The statute provides that \u8220\'3f[w]hoever actively induces infringement of a patent shall be liable as an infringer.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. However, direct infringement is a necessary predicate for a finding of induced infringement in the usual patent infringement case. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033496706&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_708_2117&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2117" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Limelight Networks, Inc. v. Akamai Techs., Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 134 S.Ct. 2111, 2117, 189 L.Ed.2d 52 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. It also \u8220\'3fmust be established that the defendant possessed specific intent to encourage another\rquote s infringement and not merely that the defendant had knowledge of the acts alleged to constitute inducement.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2010878868&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1306&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1306" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
DSU Med. Corp. v. JMS Co.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 471 F.3d 1293, 1306 (Fed. Cir. 2006)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (en banc in relevant part) (internal quotation omitted). Circumstantial evidence can support a finding of specific intent to induce infringement. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023571452&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1060&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1060" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
AstraZeneca LP v. Apotex, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (
}
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
AstraZeneca I
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ), 633 F.3d 1042, 1060 (Fed. Cir. 2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1988078737&pubNum=0000350&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_350_668&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_668" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Water Techs. Corp. v. Calco, Ltd.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 850 F.2d 660, 668 (Fed. Cir. 1988)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B152044320422_15}{\*\bkmkend co_anchor_B152044320422_15}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B162044320422_15}{\*\bkmkend co_anchor_B162044320422_15}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We have held that \u8220\'3f[i]nducement can be found where there is \u8216\'3f[e]vidence of active steps taken to encourage direct infringement,\u8217\'3f which can in turn be found in \u8216\'3fadvertising an infringing use or instructing how to engage in an infringing use.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036222044&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_630&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_630" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Takeda Pharm. U.S.A., Inc. v. W.-Ward Pharm. Corp.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 785 F.3d 625, 630\u8211\'3f31 (Fed. Cir. 2015)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (second alteration in original) (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2006858550&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_936&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_936" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Metro\u8211\'3fGoldwyn\u8211\'3fMayer Studios Inc. v. Grokster, Ltd.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 545 U.S. 913, 936, 125 S.Ct. 2764, 162 L.Ed.2d 781 (2005)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ). Where \u8220\'3fthe proposed label instructs users to perform the patented method ... the proposed label may provide evidence of [the ANDA applicant\rquote s] affirmative intent to induce infringement.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023571452&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1060&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1060" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
AstraZeneca I
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 633 F.3d at 1060
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. When proof of specific intent depends on the label accompanying the marketing of a drug inducing infringement by physicians, \u8220\'3f[t]he label must encourage, recommend, or promote infringement.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036222044&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_631&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_631" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Takeda
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 785 F.3d at 631
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The contents of the label itself may permit the inference of specific intent to encourage, recommend, or promote infringement. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043134164&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_646&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_646" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Sanofi v. Watson Labs. Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 875 F.3d 636, 646 (Fed. Cir. 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
West-Ward argues that the district court clearly erred in finding that its proposed label \u8220\'3fsatisfies\u8221\'3f the asserted claims because the language of the label itself cannot constitute direct infringement of the asserted method claims. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_7903_432&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_432" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Opinion
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 203 F.Supp.3d at 432
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. West-Ward also contends that the court clearly erred in finding that Dr. Alva practiced the asserted claims because he never administered an allegedly infringing dose to a poor metabolizer.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Vanda responds that it did not need to prove instances of direct infringement by physicians because this is a Hatch-Waxman case where infringement is statutorily-defined to be the filing of an ANDA or an amendment thereto, not by selling a product. Even though not required, Vanda contends, it identified a doctor, Dr. Alva, who practiced the steps of the asserted claims with Fanapt\u174\'3f. Vanda argues that the asserted claims do not require that a single physician administer iloperidone to both poor and non-poor CYP2D6 metabolizers, and that West-Ward\rquote s argument to the contrary is waived because it was raised for the first time on appeal.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We agree with Vanda that a patentee does not need to prove an actual past instance of direct infringement by a physician to establish infringement under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. As we have explained, \u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
section 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 makes it possible for a patent owner to have the court determine whether, if a particular drug 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
were
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 put on the market, it 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
would
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 infringe the relevant patent.\u8221\'3f 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1130_15}{\*\bkmkend co_pp_sp_506_1130_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1130
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1995220011&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1135&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1135" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Bristol-Myers 
}
}
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Squibb
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 69 F.3d at 1135
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphases in original). A 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_9e660000185f2" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 infringement suit differs from typical infringement suits in that the infringement inquiries \u8220\'3fare 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
hypothetical
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because the allegedly infringing product has not yet been marketed.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2003082816&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1365&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1365" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Warner-Lambert
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 316 F.3d at 1365
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1997083946&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1570&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1570" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Glaxo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 110 F.3d at 1570
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe relevant inquiry is whether patentee has proven by a preponderance of the evidence that the alleged infringer will likely market an infringing product.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Similarly, patentees in Hatch-Waxman litigations asserting method patents do not have to prove that prior use of the NDA-approved drug satisfies the limitations of the asserted claims. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043134164&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_643&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_643" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Sanofi
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 875 F.3d at 643
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (affirming inducement finding where the district court found \u8220\'3fthe inducing act will be the marketing by [ANDA applicants] of their generic dronedarone drugs with the label described\u8221\'3f and \u8220\'3fthe induced act will be the administration of dronedarone by medical providers to patients meeting the criteria set forth in the [claims at issue]\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2040743290&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1368&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1368" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Eli Lilly & Co. v. Teva Parenteral Meds., Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 845 F.3d 1357, 1368 (Fed. Cir. 2017)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (explaining \u8220\'3fwe have not required evidence regarding the general prevalence of the induced activity\u8221\'3f); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023571452&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1057&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1057" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
AstraZeneca I
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 633 F.3d at 1057
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (affirming district court\rquote s grant of a preliminary injunction based on claims of induced infringement where the district court found that \u8220\'3fthe proposed label would cause some users to infringe the asserted method claims\u8221\'3f); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2003082816&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1364&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1364" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Warner-Lambert
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 316 F.3d at 1364
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe infringement case is therefore limited to an analysis of whether what the generic drug maker is requesting authorization for in the ANDA would be an act of infringement if performed.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Accordingly, Vanda can satisfy its burden to prove the predicate direct infringement by showing that if the proposed ANDA product were marketed, it would infringe the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The district court made factual findings that the proposed label \u8220\'3frecommends\u8221\'3f that physicians perform the claimed steps, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_7903_432&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_432" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Opinion
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 203 F.Supp.3d at 432\u8211\'3f33
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, and its analysis of the proposed label to assess potential direct infringement by physicians was proper under our precedent. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2034181324&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1408&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1408" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ferring B.V. v. Watson Labs., Inc.-Fla.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 764 F.3d 1401, 1408 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe infringement determination is thus based on consideration of all the relevant evidence, and because drug manufacturers are bound by strict statutory provisions to sell only those products that comport with the ANDA\rquote s description of the drug, the ANDA itself dominates the analysis.\u8221\'3f (internal quotation marks and alterations omitted) ); 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023571452&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1060&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1060" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
AstraZeneca I
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 633 F.3d at 1060
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (explaining that the district court \u8220\'3fcorrectly determined\u8221\'3f that language in the ANDA label \u8220\'3fwould inevitably lead some consumers to practice the claimed method\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Turning to specific intent, West-Ward argues that Vanda failed to prove that its proposed label would \u8220\'3f \u8216\'3fencourage\u8217\'3f or \u8216\'3frecommend\u8217\'3f a direct infringer (a psychiatrist or other physician) to perform each step of the claimed methods.\u8221\'3f Appellant Br. 36 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2036222044&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_631&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_631" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Takeda
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 785 F.3d at 631
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). West-Ward contends that the substantial number of noninfringing uses precludes a finding of specific intent as a matter of law. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2003082816&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1365&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1365" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Warner-Lambert
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 316 F.3d at 1365
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Vanda responds that the district court did not clearly err in finding that the proposed label recommends performance of all the claimed steps. Vanda argues that potential noninfringing uses do not preclude a finding of specific intent to induce infringement in this case.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We agree with Vanda that the district court did not clearly err in finding induced infringement of independent claims 1, 9, 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1131_15}{\*\bkmkend co_pp_sp_506_1131_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1131
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 13.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00082044320422_ID0EU5DI_15}{\*\bkmkend co_fnRef_B00082044320422_ID0EU5DI_15}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00082044320422_15" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
8
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Section 2 of the proposed label is entitled \u8220\'3fDosage and Administration.\u8221\'3f J.A. 15105 \u167\'3f 2. Section 2.1 entitled, \u8220\'3fUsual Dose,\u8221\'3f states:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Iloperidone must be titrated slowly from a low starting dose.... The recommended starting dose for iloperidone tablets is 1 mg twice daily. Dose increases to reach the 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
target range
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of 6 to 12 mg twice daily (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
12 to 24 mg/day
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ) may be made with daily dosage adjustments not to exceed 2 mg twice daily (4 mg/day). The 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
maximum recommended dose
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is 12 mg twice daily (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
24 mg/day
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 ).... Prescribers should be mindful of the fact that patients need to be titrated to an effective dose of iloperidone.
\par 
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u167\'3f 2.1 (emphases added). Section 2.2, entitled \u8220\'3fDosage in Special Populations,\u8221\'3f states: \u8220\'3f
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Dosage adjustment for
}
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
patients taking iloperidone who are poor metabolizers of CYP2D6:
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Iloperidone dose should be 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
reduced by one-half
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 for poor metabolizers of CYP2D6 [
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see
}
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Pharmacokinetics (12.3)
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ].\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u167\'3f 2.2 (second emphasis added).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section 12.3 of the proposed label, entitled \u8220\'3fPharmacokinetics,\u8221\'3f states:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Approximately 7 to 10% of Caucasians and 3 to 8% of Black/African Americans lack the capacity to metabolize CYP2D6 substrates and are classified as poor metabolizers (PM), whereas the rest are intermediate, extensive or ultrarapid metabolizers. Co-administration of iloperidone with known strong inhibitors of CYP2D6 like 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3ab2a1c5475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
fluoxetine
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 results in a 2.3 fold increase in iloperidone plasma exposure, and therefore one-half of the iloperidone dose should be administered.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Similarly, PMs of CYP2D6 have higher exposure to iloperidone compared with [extensive metabolizers] and 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
PMs should have their dose reduced by one-half. Laboratory tests are available to identify CYP2D6 PMs
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
J.A. 15121 \u167\'3f 12.3 (emphasis added).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Thus, the district court did not clearly err in finding that \u167\'3f 12.3 \u8220\'3frecommends that practitioners perform or have performed a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 assay to determine whether patients are CYP2D6 poor metabolizers.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_7903_432&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_432" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Opinion
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 203 F.Supp.3d at 432
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Experts for both parties testified that the referred-to \u8220\'3flaboratory tests\u8221\'3f are \u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 tests.\u8221\'3f J.A. 6939 (234:8\u8211\'3f235:13) (Vanda\rquote s expert); J.A. 7103\u8211\'3f04 (566:10\u8211\'3f568:2) (West-Ward\rquote s expert). The district court thus found that \u8220\'3fwhen the label states that \u8216\'3flaboratory tests\u8217\'3f are available to identify poor metabolizers, the label is referring to \u8216\'3fgenotyping tests.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_7903_433&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_433" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Opinion
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 203 F.Supp.3d at 433
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing testimony of both parties\rquote  experts). We discern no clear error in this finding.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The label instructs practitioners that \u8220\'3fPMs should have their dose reduced by one-half. [Genotyping tests] are available to identify CYP2D6 PMs.\u8221\'3f J.A. 15121 \u167\'3f 12.3. The court did not clearly err in finding that this constitutes a recommendation to perform genotyping tests on iloperidone patients. That West-Ward introduced other evidence that could have supported a contrary finding does not compel the conclusion that the district court clearly erred. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1132_15}{\*\bkmkend co_pp_sp_506_1132_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1132
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1985114055&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_574&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_574" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Anderson v. City 
}
}
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
of Bessemer City
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 470 U.S. 564, 574, 105 S.Ct. 1504, 84 L.Ed.2d 518 (1985)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fWhere there are two permissible views of the evidence, the factfinder\rquote s choice between them cannot be clearly erroneous.\u8221\'3f
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). Moreover, the court\rquote s decision to credit the plausible testimony of certain witnesses and reject the testimony of West-Ward\rquote s witness as not credible, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_7903_433&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_433" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Opinion
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 203 F.Supp.3d at 433
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8220\'3fcan virtually never be clear error,\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1985114055&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_575&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_575" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Anderson
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 470 U.S. at 575, 105 S.Ct. 1504
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We reject West-Ward\rquote s contention that the lack of an express finding by the district court that the label recommends obtaining a biological sample requires a remand. The district court found induced infringement of the independent claims, which necessarily required a finding of inducement of the limitation requiring \u8220\'3fobtaining or having obtained a biological sample from the patient.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 17 ll. 7\u8211\'3f8 (claim 1), col. 18 ll. 9\u8211\'3f10 (claim 9), col. 18 ll. 34\u8211\'3f
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (claim 13). West-Ward has pointed to no evidence in the record to dispute the testimony of Vanda\rquote s witnesses at trial that the genotyping assays the court found were recommended by the label require obtaining a biological sample. J.A. 6928 (190:14\u8211\'3f191:1); J.A. 6939 (235:18\u8211\'3f23). Given this undisputed evidence and the court\rquote s finding that the label recommends genotyping assays, we see no clear error in the court\rquote s implicit finding that the proposed label recommends obtaining a biological sample. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1995252576&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1090&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1090" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Para-Ordnance Mfg., Inc. v. SGS Importers Int\rquote l, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 73 F.3d 1085, 1090 (Fed. Cir. 1995)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (explaining that \u8220\'3f[f]rom the decision of the district court, we can, and do, accept the implicit fact-finding\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The district court also did not clearly err in finding that \u8220\'3f[t]he label recommends oral administration of iloperidone tablets at 12 to 24 mg/day to non-genotypic CYP2D6 poor metabolizers and 12 mg/day or less to genotypic CYP2D6 poor metabolizers.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_7903_432&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_432" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Opinion
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 203 F.Supp.3d at 432
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing J.A. 15105 \u167\'3f\u167\'3f 2.1, 2.2). The label recommends a \u8220\'3f[u]sual\u8221\'3f target dose range (12 to 24 mg/day) and maximum dose (24 mg/day) and then instructs medical providers to \u8220\'3freduce[ ]\u8221\'3f the dose for genetic CYP2D6 poor metabolizers (a \u8220\'3f[s]pecial population\u8221\'3f) \u8220\'3fby one-half.\u8221\'3f J.A. 15015 \u167\'3f\u167\'3f 2.1, 2.2; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 J.A. 15103; J.A. 15121 \u167\'3f 12.3. A one-half reduction of the usual dose amounts yields a target dose range of 6 to 12 mg/day and a maximum dose of 12 mg/day for poor metabolizers. That the label also directs a medical provider to titrate the dosage does not negate its clear recommendations on ultimate dosage range and maximum amount.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Similarly, the fact that the target dose range for genotypic non-poor metabolizers (12 to 24 mg/day) includes 12 mg/day does not compel a finding of noninfringement. The independent claims require administering \u8220\'3fgreater than 12 mg/day, up to 24 mg/day\u8221\'3f of iloperidone to non-poor metabolizers. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 17 ll. 17\u8211\'3f20 (claim 1), col. 18 ll. 16\u8211\'3f18 (claim 9), col. 18 ll. 44\u8211\'3f47 (claim 13). Even if not every practitioner will prescribe an infringing dose, that the target dose range \u8220\'3finstructs users to perform the patented method\u8221\'3f is sufficient to \u8220\'3fprovide evidence of [West-Ward\rquote s] affirmative intent to induce infringement.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2023571452&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1060&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1060" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
AstraZeneca I
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 633 F.3d at 1060
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2040743290&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1369&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1369" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Eli Lilly
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 845 F.3d at 1369
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (explaining that \u8220\'3fevidence that the product labeling that Defendants seek would inevitably lead some physicians to infringe establishes the requisite intent for inducement\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Finally, West-Ward\rquote s reliance on 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2003082816&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Warner-Lambert
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, an off-label use case, is misplaced. In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2003082816&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Warner-Lambert
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, we explained that \u8220\'3fit defies common sense to expect that [ANDA applicant] will actively promote the sale of its approved [ANDA product], in contravention of FDA regulations, for a 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1133_15}{\*\bkmkend co_pp_sp_506_1133_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1133
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 use that (a) might infringe [NDA holder\rquote s] patent and (b) constitutes such a small fraction of total sales.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2003082816&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1365&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1365" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Warner-Lambert
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 316 F.3d at 1365
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In the context of that off-label use case where there were \u8220\'3fsubstantial noninfringing uses,\u8221\'3f we declined to \u8220\'3finfer\u8221\'3f intent to induce infringement. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2003082816&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Here, the district court found that the proposed label itself recommends infringing acts.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B172044320422_15}{\*\bkmkend co_anchor_B172044320422_15}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Accordingly, even if the proposed ANDA product has \u8220\'3fsubstantial noninfringing uses,\u8221\'3f West-Ward may still be held liable for induced infringement. \u8220\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_a83b000018c76" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section 271(b)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, on inducement, does not contain the \u8216\'3fsubstantial noninfringing use\u8217\'3f restriction of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_4b24000003ba5" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
section 271(c)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, on contributory infringement.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043134164&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_646&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_646" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Sanofi
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 875 F.3d at 646
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Thus, \u8220\'3fa person can be liable for inducing an infringing use of a product even if the product has substantial noninfringing uses....\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2043134164&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citing 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2006858550&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_934&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_934" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Grokster
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 545 U.S. at 934\u8211\'3f37, 125 S.Ct. 2764
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ic75415a148c011ecb4b0a4d54f706}{\*\bkmkend co_anchor_Ic75415a148c011ecb4b0a4d54f706}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
III. Patent Subject Matter Eligibility
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B182044320422_15}{\*\bkmkend co_anchor_B182044320422_15}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We next address whether the asserted claims are directed to patent-eligible subject matter. West-Ward argues that the asserted claims are ineligible under 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 because they are directed to a natural relationship between iloperidone, CYP2D6 metabolism, and QT prolongation, and add nothing inventive to those natural laws and phenomena. West-Ward contends that the asserted claims are indistinguishable from those held invalid in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Association for Molecular Pathology v. Myriad Genetics, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 569 U.S. 576, 133 S.Ct. 2107, 186 L.Ed.2d 124 (2013)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Services v. Prometheus Laboratories, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. 66, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Vanda responds that the asserted claims are patent-eligible under 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at both steps of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
/
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Vanda contends that the district court erred in holding that the asserted claims are directed to a law of nature. According to Vanda, the court\rquote s \u8220\'3fconclusions that the asserted claims \u8216\'3fdepend upon,\u8217\'3f \u8216\'3ftouch[ ] upon,\u8217\'3f and \u8216\'3faddress\u8217\'3f laws of nature and natural phenomena do not, as a matter of law, establish that the asserted claims are 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
directed to
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 a patent-ineligible concept under Step 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
/
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis.\u8221\'3f Appellee Br. 45 (alteration and emphasis in original).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf1 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 of the Patent Act states that \u8220\'3f[w]hoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. However, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3fcontains an important implicit exception\u8221\'3f: \u8220\'3f \u8216\'3flaws of nature, natural phenomena, and abstract ideas\u8217\'3f are not patentable.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_70&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_70" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 70, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (alteration omitted) (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1981109598&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_185&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_185" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Diamond v. Diehr
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 450 U.S. 175, 185, 101 S.Ct. 1048, 67 L.Ed.2d 155 (1981)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Supreme Court has established a two-step framework to determine patent subject matter eligibility under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
First, we determine whether the claims at issue are directed to one of those patent-ineligible concepts. If so, we then ask, \u8220\'3f[w]hat else is there in the claims before us?\u8221\'3f To answer that question, we consider the elements of each claim both individually and \u8220\'3fas an ordered combination\u8221\'3f to determine whether the additional elements \u8220\'3ftransform the nature of the claim\u8221\'3f into a patent-eligible application. We have described step two of this analysis as a search for an \u8220\'3f \u8216\'3finventive concept\u8217\'3f \u8221\'3f\u8212\'3f
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.,
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 an element or combination of elements that is \u8220\'3fsufficient to ensure that the patent in practice amounts to significantly more than a patent upon the [ineligible concept] itself.\u8221\'3f
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1134_15}{\*\bkmkend co_pp_sp_506_1134_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1134
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_708_2355&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_2355" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice Corp. Pty. v. CLS Bank Int\rquote l
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8211\'3f\u8211\'3f\u8211\'3f U.S. \u8211\'3f\u8211\'3f\u8211\'3f\u8211\'3f, 134 S.Ct. 2347, 2355, 189 L.Ed.2d 296 (2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (citations omitted) (alteration in original) (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_72&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_72" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 72\u8211\'3f73, 75\u8211\'3f79, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B192044320422_15}{\*\bkmkend co_anchor_B192044320422_15}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B202044320422_15}{\*\bkmkend co_anchor_B202044320422_15}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Step one requires determining \u8220\'3fwhether the claims at issue are 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
directed to
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 one of those patent-ineligible concepts.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038839002&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1335&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1335" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Enfish, LLC v. Microsoft Corp.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 822 F.3d 1327, 1335 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Supreme Court has cautioned that \u8220\'3ftoo broad an interpretation of\u8221\'3f ineligible subject matter \u8220\'3fcould eviscerate patent law\u8221\'3f because \u8220\'3fall inventions at some level embody, use, reflect, rest upon, or apply laws of nature, natural phenomena, or abstract ideas.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_71&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_71" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 71, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Accordingly, at step one, \u8220\'3fit is not enough to merely identify a patent-ineligible concept underlying the claim; we must determine whether that patent-ineligible concept is what the claim is \u8216\'3fdirected to.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1050&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1050" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Rapid Litig. Mgmt. Ltd. v. CellzDirect, Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 827 F.3d 1042, 1050 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. If the claims are not directed to a patent ineligible concept at step one, we need not address step two of the inquiry. See 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2038839002&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1339&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1339" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Enfish, 822 F.3d at 1339
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. That is the case here.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Consistent with Supreme Court precedent, we agree with Vanda that the asserted claims are not directed to patent-ineligible subject matter.
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00092044320422_ID0ECCBK_15}{\*\bkmkend co_fnRef_B00092044320422_ID0ECCBK_15}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00092044320422_15" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
9
}}}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Claim 1 recites \u8220\'3f[a] method for treating a patient with iloperidone, wherein the patient is suffering from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 17 ll. 2\u8211\'3f3. Claim 1 requires specific steps: (1) determining the patient\rquote s CYP2D6 metabolizer genotype by (a) obtaining a biological sample and (b) performing a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 assay; and (2) administering specific dose ranges of iloperidone depending on the patient\rquote s CYP2D6 genotype. Id. col. 17 ll. 2\u8211\'3f25.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
West-Ward contends that the Supreme Court held that similar claims were patent ineligible in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The patent in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claimed a method for \u8220\'3foptimizing\u8221\'3f the dosage of thiopurine drugs by administering thiopurine drugs to a patient and measuring the level of certain metabolites in the blood, wherein the level of metabolites indicates whether to adjust the dosage. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_74&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_74" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 74\u8211\'3f75, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Supreme Court held that the claims recited a natural law, and did not include any \u8220\'3fadditional features that provide practical assurance that the process is more than a drafting effort designed to monopolize the law of nature itself.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 77, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This case, however, is not 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. First, the claims in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 were not directed to a novel method of treating a disease. Instead, the claims were directed to a diagnostic method based on the \u8220\'3frelationships between concentrations of certain metabolites in the blood and the likelihood that a dosage of a thiopurine drug will prove ineffective or cause harm.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 This \u8220\'3frelation is a consequence of the ways in which thiopurine compounds are metabolized by the body\u8212\'3fentirely natural processes. And so a patent that simply describes that relation sets forth a natural law.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Although the representative claim in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 recited administering a thiopurine drug to a patient, the claim as a whole was not directed to the application of a drug to treat a particular disease. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_708_74&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_74" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 74, 87, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Importantly, the Supreme Court explained that the administering step was akin to a limitation that tells engineers to apply a known natural relationship or to apply an abstract idea with computers. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_708_78&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_78" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 78, 132 S.Ct. 1289
}}}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1135_15}{\*\bkmkend co_pp_sp_506_1135_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1135
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (comparing the claim in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 to \u8220\'3fEinstein telling linear accelerator operators about his basic law and then trusting them to use it where relevant\u8221\'3f). To further underscore the distinction between method of treatment claims and those in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the Supreme Court noted that \u8220\'3f[u]nlike, say, a typical patent on a new drug or a new way of using an existing drug, the patent claims do not confine their reach to particular applications of those laws.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_708_87&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_708_87" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 87, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In this case, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims are directed to a method of using iloperidone to treat 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The inventors recognized the relationships between iloperidone, CYP2D6 metabolism, and QTc prolongation, but that is not what they claimed. They claimed an application of that relationship. Unlike the claim at issue in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the claims here require a treating doctor to administer iloperidone in the amount of either (1) 12 mg/day or less or (2) between 12 mg/day to 24 mg/day, depending on the result of a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 assay. The specification further highlights the significance of the specific dosages by explaining how certain ranges of administered iloperidone correlate with the risk of QTc prolongation. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See, e.g.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at col. 4 ll. 1\u8211\'3f15. Thus, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims are \u8220\'3fa new way of using an existing drug\u8221\'3f that is safer for patients because it reduces the risk of QTc prolongation. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_87&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_87" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 87, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moreover, unlike the claim in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, to the extent that preemption is a concern, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims do not \u8220\'3ftie up the doctor\rquote s subsequent treatment decision.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 86, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The claim in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 did not go beyond recognizing (
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
i.e.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8220\'3findicates\u8221\'3f) a need to increase or decrease a dose. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 75, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. In 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, \u8220\'3fa doctor ... could violate the patent even if he did not actually alter his treatment decision in the light of the test.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 The claim was not a treatment claim. It was \u8220\'3fnot limited to instances in which the doctor actually decreases (or increases) the dosage level where the test results suggest that such an adjustment is advisable.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 76, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Thus, the claim in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 did not involve doctors 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
using
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the natural relationship between the metabolite level and lessening \u8220\'3fthe likelihood that a dosage of a thiopurine drug will prove ineffective or cause harm.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 77, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The claims in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 therefore \u8220\'3ftie up the doctor\rquote s subsequent treatment decision whether that treatment does, or does not, change in light of the inference he has drawn using the correlations. And they threaten to inhibit the development of more refined treatment recommendations....\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 86\u8211\'3f87, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Here, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims recite the steps of carrying out a dosage regimen based on the results of genetic testing. The claims require doctors to \u8220\'3finternally administer[ ] iloperidone to the patient in an amount of 12 mg/day or less\u8221\'3f if the patient has a CYP2D6 poor metabolizer genotype; and \u8220\'3finternally administer[ ] iloperidone to the patient in an amount that is greater than 12 mg/day, up to 24 mg/day\u8221\'3f if the patient does not have a CYP2D6 poor metabolizer genotype. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 17 ll. 13\u8211\'3f20. These are treatment steps. In contrast, as shown above, the claim in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 stated that the metabolite level in blood simply \u8220\'3findicates\u8221\'3f a need to increase or decrease dosage, without prescribing a specific dosage regimen or other added steps to take as a result of that indication. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_75&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_75" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 75, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Here, the claims do not broadly \u8220\'3ftie up the doctor\rquote s subsequent treatment decision.\u8221\'3f
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 86, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Our decision in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 supports concluding that these claims are patent eligible. In that case, we held that \u8220\'3fa method of producing a desired preparation of 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1136_15}{\*\bkmkend co_pp_sp_506_1136_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1136
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 multi-cryopreserved hepatocytes cells\u8221\'3f was patent eligible. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1047&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1047" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 827 F.3d at 1047
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. We explained that \u8220\'3f[t]he end result of the ... claims is not simply an observation or detection of the ability of hepatocytes to survive multiple freeze-thaw cycles. Rather, the claims [were] directed to a new and useful method of preserving hepatocyte cells.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1048&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1048" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1048
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. We further emphasized that \u8220\'3fthe natural ability of the subject matter to 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
undergo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the process does not make the claim \u8216\'3fdirected to\u8217\'3f that natural ability.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1049&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1049" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1049
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis in original). Otherwise, claims directed to actually \u8220\'3ftreating 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 with chemotherapy\u8221\'3f or \u8220\'3ftreating headaches with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af17fb7475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
aspirin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f would be patent ineligible. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}}}
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Nor does 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 compel a different outcome. The Supreme Court in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 held \u8220\'3fthat a naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but that cDNA is patent eligible because it is not naturally occurring.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_580&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_580" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Myriad
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 569 U.S. at 580, 133 S.Ct. 2107
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The Court was careful to note that \u8220\'3fmethod claims\u8221\'3f and \u8220\'3fpatents on new applications of knowledge about [particular] genes\u8221\'3f were \u8220\'3f
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
not
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 implicated by [its] decision.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2030717666&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 595\u8211\'3f96, 133 S.Ct. 2107
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis in original). The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 does not claim naturally occurring DNA segments. Rather, the asserted claims fall squarely within categories of claims that the Court stated were not implicated by its decision.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
At bottom, the claims here are directed to a specific method of treatment for specific patients using a specific compound at specific doses to achieve a specific outcome. They are different from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. They recite more than the natural relationship between CYP2D6 metabolizer genotype and the risk of QTc prolongation. Instead, they recite a method of treating patients based on this relationship that makes iloperidone safer by lowering the risk of QTc prolongation. Accordingly, the claims are patent eligible.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ic762949148c011ecb4b0a4d54f706}{\*\bkmkend co_anchor_Ic762949148c011ecb4b0a4d54f706}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
IV. Written Description
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B212044320422_15}{\*\bkmkend co_anchor_B212044320422_15}
}
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B222044320422_15}{\*\bkmkend co_anchor_B222044320422_15}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We next consider West-Ward\rquote s argument that the district court erred in finding that the claims are not invalid for lack of adequate written description. To satisfy the written description requirement the patent disclosure must \u8220\'3freasonably convey[ ] to those skilled in the art that the inventor had possession of the claimed subject matter as of the filing date.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2021584873&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1351&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1351" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ariad Pharm., Inc. v. Eli Lilly & Co.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 598 F.3d 1336, 1351 (Fed. Cir. 2010)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (en banc). Whether a claim satisfies the written description requirement is a question of fact that we review for clear error following a bench trial. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032909107&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1190&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1190" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alcon Research
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 745 F.3d at 1190
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
West-Ward argues that the asserted claims are invalid for lack of written description because nothing in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 demonstrates possession of the claimed dosage ranges for poor and non-poor CYP2D6 metabolizer genotypes. West-Ward contends that the description does not contain experiments with doses of 12 mg/day or less given to poor metabolizers, and reports data that does not support the claimed poor-metabolizer dose range.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Vanda responds that the district court did not clearly err in finding that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 adequately describes the claimed dosages for poor metabolizers. Vanda contends that West-Ward waived any written description challenge to the dosages for non-poor metabolizers, and that West-Ward\rquote s argument is, in any event, meritless.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We agree with Vanda that the district court did not clearly err in finding that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 contains adequate written description for the claimed \u8220\'3f12 mg/day or less\u8221\'3f dosage range for poor metabolizers. The patent reports the results of tests 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1137_15}{\*\bkmkend co_pp_sp_506_1137_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1137
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 comparing the concentrations of P88 and P95, iloperidone\rquote s two main metabolites, and changes in QTc interval upon administration of doses of iloperidone, both with and without the addition of a CYP2D6 inhibitor, to individuals with wildtype or a poor metabolizer genotype associated with two common CYP2D6 polymorphisms. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 4 l. 62\u8211\'3fcol. 10 l. 56. The patent reports that \u8220\'3fQTc prolongation is correlated to the ratios of P88/P95 and (iloperidone+P88)/P95.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 9 ll. 57\u8211\'3f58.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 further explains that the reported results \u8220\'3fshow that patients can be more safely treated with iloperidone if the dose of iloperidone is adjusted based on the CYP2D6 genotype of each patient,\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 9 ll. 31\u8211\'3f34; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
accord 
}
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 2 ll. 15\u8211\'3f24, and provides examples of such doses, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 9 ll. 34\u8211\'3f47, col. 11 ll. 22\u8211\'3f28. For a poor metabolizer, those examples include reducing the dose of iloperidone administered by \u8220\'3f75% or less, 50% or less, or 25% or less of the dose typically administered to a patient having a CYP2D6 genotype that results in a CYP2D6 protein\u8221\'3f with wildtype activity. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 9 ll. 34\u8211\'3f43. The patent then provides a specific example of a dose for non-poor metabolizers, \u8220\'3f24 mg per day,\u8221\'3f and the appropriate reduction for a poor metabolizer \u8220\'3freduced dosage of 18, 12, or 6 mg per day.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 9 ll. 43\u8211\'3f47. The disclosure of a dose outside of the claimed range does not compel a finding that the asserted claims lack adequate written description. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033982646&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1359&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1359" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Scriptpro, LLC v. Innovation Assocs., Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 762 F.3d 1355, 1359 (Fed. Cir. 2014)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fIt is common, and often permissible, for particular claims to pick out a subset of the full range of described features, omitting others.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The district court heard testimony that the data reported in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 show a trend for higher QTc prolongation among genotypic CYP2D6 poor metabolizers given a 24 mg/day dose, and support a reduction in dose for CYP2D6 poor metabolizers by a factor of 1.5 to 3.5. West-Ward introduced some testimony challenging the sufficiency of the data and the lack of statistical analysis, but that does not render the court\rquote s reliance on testimony supporting validity impermissible. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1985114055&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_574&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_574" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Anderson
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 470 U.S. at 574\u8211\'3f75, 105 S.Ct. 1504
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. On this record, we cannot say that the district court clearly erred in finding that the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 sufficiently discloses the claimed range for poor metabolizers.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B232044320422_15}{\*\bkmkend co_anchor_B232044320422_15}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Moreover, West-Ward waived its written description challenge with respect to non-poor metabolizers by failing to properly present it to the trial court. The Supreme Court has observed that as a \u8220\'3fgeneral rule ... a federal appellate court does not consider an issue not passed upon below.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1976142445&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_120&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_120" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Singleton v. Wulff
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 428 U.S. 106, 120, 96 S.Ct. 2868, 49 L.Ed.2d 826 (1976)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Although appellate courts have discretion to decide when to deviate from this general waiver rule, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1976142445&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 121, 96 S.Ct. 2868
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, West-Ward has not articulated a basis for us to reach this issue for the first time on appeal and we discern none, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2026945608&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1282&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1282" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
HTC Corp. v. IPCom GmbH & Co., KG
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 667 F.3d 1270, 1282\u8211\'3f83 (Fed. Cir. 2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
West-Ward points only to a single page in each of its opening and reply post-trial briefs to support its claim that this issue is not waived. Those pages make passing reference to the dosage range for non-poor metabolizers in the context of the written description arguments West-Ward advanced for poor metabolizers. 
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
West-Ward does not point us to any argument or evidence that it advanced before the district court specifically with respect to non-poor metabolizers. Indeed, West-Ward did not identify lack of written description with respect to non-poor metabolizer dose range in its pretrial submissions identifying the issues to be tried. West-Ward has thus waived any further argument that the 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1138_15}{\*\bkmkend co_pp_sp_506_1138_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1138
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 non-poor metabolizer dosage range was not adequately supported by the written description.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ic76812d148c011ecb4b0a4d54f706}{\*\bkmkend co_anchor_Ic76812d148c011ecb4b0a4d54f706}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
V. Injunctive Relief
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B242044320422_15}{\*\bkmkend co_anchor_B242044320422_15}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We finally address the propriety of the injunctive relief awarded by the district court. West-Ward argues that the injunctions were not supported by the courts \u8220\'3fgeneral equitable power,\u8221\'3f and the lack of jurisdiction or an infringing act under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 precludes upholding the injunctions under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_22700000861f0" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(4)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. West-Ward contends that \u8220\'3fthe FDA has independently determined that litigation over the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 should not delay approval of iloperidone ANDAs filed before the patent issued and was submitted to the agency.\u8221\'3f Appellant Br. 62 (citing https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/207231Orig1s000
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i1 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
l
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
tr.pdf). West-Ward further argues that because Vanda did not cross-appeal the denial of an injunction under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_22700000861f0" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(4)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 that provision cannot be an alternative ground to uphold the FDA injunction.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Vanda responds that the district court\rquote s injunctions can be affirmed under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_22700000861f0" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(4)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and that the court erred in not granting relief pursuant to that provision. In any event, Vanda contends that the district court did not err in granting injunctive relief pursuant to its equitable powers against West-Ward.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We agree with Vanda that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_22700000861f0" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(4)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 supports the injunctive relief granted by the district court. As discussed above, the district court properly held that Vanda had established infringement of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_22700000861f0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section 271(e)(4)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 provides in relevant part:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
For an act of infringement described in paragraph (2)\u8212\'3f
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(A) the court shall order the effective date of any approval of the drug or veterinary biological product involved in the infringement to be a date which is not earlier than the date of the expiration of the patent which has been infringed,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
(B) injunctive relief may be granted against an infringer to prevent the commercial manufacture, use, offer to sell, or sale within the United States or importation into the United States of an approved drug, veterinary biological product, or biological product,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
...
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
The remedies prescribed by subparagraphs (A), (B), (C), and (D) are the only remedies which may be granted by a court for an act of infringement described in paragraph (2), except that a court may award attorney fees under section 285.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_22700000861f0" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(4)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_22700000861f0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Section 271(e)(4)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 contains no carve-out for patents that issue after the date of submission of the original ANDA. Moreover, the statute explicitly states that \u8220\'3fthe only remedies\u8221\'3f a court may grant following an infringement finding under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 are pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_f4aa000038542" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(4)(A)\u8211\'3f(D)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and attorney fees pursuant to \u167\'3f 285. Accordingly, upon a finding of patent infringement under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, the district court must order remedies in accordance with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_22700000861f0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(4)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
West-Ward\rquote s reliance on the FDA\rquote s letter approving a different company\rquote s ANDA 20-7231 for iloperidone tablets is misplaced. The letter indicates that because the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 was \u8220\'3fsubmitted to the [FDA] after submission of [that] ANDA,\u8221\'3f litigation with respect to the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3fwould not create a statutory stay of approval.\u8221\'3f https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2016/207231Orig1s000
}
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \i1 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
l
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
tr.pdf. The FDA letter merely recognizes that the issuance of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 after submission of that ANDA 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1139_15}{\*\bkmkend co_pp_sp_506_1139_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1139
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 renders the thirty-month statutory stay inapplicable. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_83fb0000a4d76" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(j)(5)(B)(iii)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (providing that triggering of thirty-month stay requires, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
inter alia
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, that the NDA holder submit necessary \u8220\'3fpatent information 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
before the date on which the application (excluding an amendment or supplement to the application
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ) ... was submitted\u8221\'3f (emphasis added) ). It says nothing about whether the FDA would or would not change the effective approval date of the ANDA pursuant to a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_f4aa000038542" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(4)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 court order if the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 were found valid and infringed. West-Ward\rquote s argument thus improperly conflates the requirements to obtain a thirty-month stay under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_83fb0000a4d76" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 355(j)(5)(B)(iii)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 with the relief available pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_22700000861f0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(4)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 following a finding of patent infringement under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In fact, where \u8220\'3fthe FDA has already approved the ANDA, the district court\rquote s [
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_f4aa000038542" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(4)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ] order would [only] alter the effective date of the application, thereby converting a final approval into a tentative approval.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2016791128&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1367&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1367" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
In re Omeprazole Patent Litig.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 536 F.3d 1361, 1367\u8211\'3f68 (Fed. Cir. 2008)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
; 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2005558672&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1281&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1281" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mylan Labs., Inc. v. Thompson
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 389 F.3d 1272, 1281\u8211\'3f84 (D.C. Cir. 2004)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (affirming revocation of final FDA approval of an ANDA and resetting of the effective approval date following a judgment of patent infringement pursuant to the district court\rquote s 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_f4aa000038542" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(4)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 order where the infringement suit was filed too late to trigger the 30-month stay). And the FDA is entitled not to set an approval date prior to the expiration of a patent that has been found to be infringed under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_f4aa000038542" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(4)(A)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 and not invalid in a Hatch-Waxman case. The district court\rquote s authority to grant the remedies provided in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_22700000861f0" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(4)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 following a judgment of patent infringement under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is not limited to those circumstances expressly listed in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_83fb0000a4d76" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355(j)(5)(B)(iii)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2015619459&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1366&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1366" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Ortho-McNeil Pharm., Inc. v. Mylan Labs., Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 520 F.3d 1358, 1366 (Fed. Cir. 2008)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fThe district court was correct to reset the effective date of an ANDA directly under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
35
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 U.S.C. \u167\'3f 271
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 without going through 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=21USCAS355&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
21 U.S.C. \u167\'3f 355
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Because we sustain the district court\rquote s infringement finding under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(2)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, we also affirm the court\rquote s grant of injunctive relief. Although the district court erred in concluding that the remedies pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_22700000861f0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(4)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 were unavailable, the court granted Vanda injunctive relief consistent with those remedies. We may thus affirm the district court\rquote s grant of injunctive relief pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_22700000861f0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(4)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B252044320422_15}{\*\bkmkend co_anchor_B252044320422_15}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Additionally, Vanda did not need to file a cross-appeal to allow us to affirm the district court\rquote s grant of injunctive relief with respect to the FDA. Without filing a cross-appeal, \u8220\'3fan appellee may \u8216\'3furge in support of a decree any matter appearing in the record, although his argument may involve an attack upon the reasoning of the lower court,\u8217\'3f but may not \u8216\'3fattack the decree with a view either to enlarging his own rights thereunder or of lessening the rights of his adversary.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1999113010&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_479&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_479" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
El Paso Nat. Gas Co. v. Neztsosie
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 526 U.S. 473, 479, 119 S.Ct. 1430, 143 L.Ed.2d 635 (1999)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1924124102&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_435&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_435" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
United States v. Am. Ry. Exp. Co.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 265 U.S. 425, 435, 44 S.Ct. 560, 68 L.Ed. 1087 (1924)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 ); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see also 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=1984115864&pubNum=0000350&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_350_844&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_350_844" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Radio Steel & Mfg. Co. v. MTD Prods., Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 731 F.2d 840, 844 (Fed. Cir. 1984)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (holding that \u8220\'3fa party will not be permitted to argue before us an issue on which it has lost and on which it has not appealed, where the result of acceptance of its argument would be a reversal or modification of the judgment rather than an affirmance\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf19 \f2 \i0 \fs20 
{\*\bkmkstart co_anchor_B262044320422_15}{\*\bkmkend co_anchor_B262044320422_15}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The district court expressly ordered relief that Vanda argues may be affirmed on the basis of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_22700000861f0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f 271(e)(4)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 J.A. 33. Thus, our affirmance does not enlarge Vanda\rquote s rights under the judgment 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1140_15}{\*\bkmkend co_pp_sp_506_1140_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1140
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 or require its amendment. Indeed, Vanda could not have filed a cross-appeal in this case because \u8220\'3f[a] party that is not adversely affected by a judgment lacks standing to [cross-appeal].\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2004656871&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1156&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1156" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
TypeRight Keyboard Corp. v. Microsoft Corp.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 374 F.3d 1151, 1156 (Fed. Cir. 2004)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
We have considered West-Ward\rquote s remaining arguments but find them to be unpersuasive.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ic770021148c011ecb4b0a4d54f706}{\*\bkmkend co_anchor_Ic770021148c011ecb4b0a4d54f706}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \i0 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb400 
Conclusion
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
For the foregoing reasons, we affirm the district court\rquote s decision.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
AFFIRMED
\par 
}
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_dissent_opinion_15}{\*\bkmkend co_dissent_opinion_15}
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ic770774248c011ecb4b0a4d54f706}{\*\bkmkend co_anchor_Ic770774248c011ecb4b0a4d54f706}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \ql \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=h&pubNum=176284&cite=0324402101&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Prost
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb400 
, Chief Judge, dissenting.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_anchor_Ic770774248c011ecb4b0a4d54f706}{\*\bkmkend co_anchor_Ic770774248c011ecb4b0a4d54f706}
\par 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
I would find the asserted patent claims to be directed to a law of nature. The majority finds the claims herein are not directed to a natural law at step one of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 analysis, but its efforts to distinguish 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 cannot withstand scrutiny. The majority relies on the claims\rquote  recitation of specific applications of the discovery underpinning the patent to find no natural law is claimed. But it conflates the inquiry at step one with the search for an inventive concept at step two. Once the natural law claimed in the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 is understood in a manner consistent with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, what remains fails to supply the requisite inventive concept to transform the natural law into patent-eligible subject matter. Although I agree with the majority\rquote s reasoning that the district court had jurisdiction under the Hatch-Waxman Act, I would not reach the issues of written description, infringement, and injunctive relief because I would find the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims ineligible subject matter. Accordingly, I respectfully dissent.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In order \u8220\'3fto transform an unpatentable law of nature into a patent-eligible application of such a law, a patent must do more than simply state the law of nature while adding the words \u8216\'3fapply it.\u8217\'3f \u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_72&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_72" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo Collaborative Servs. v. Prometheus Labs., Inc.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. 66, 72, 132 S.Ct. 1289, 182 L.Ed.2d 321 (2012)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. While the claims here do not solely state a law of nature, they do no more than simply direct the relevant audience to apply it.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 itself identifies its invention as \u8220\'3fcompris[ing] the discovery that treatment of a patient, who has lower CYP2D6 activity than a normal person, with a drug that is pre-disposed to cause QT prolongation and is metabolized by the CYP2D6 enzyme, can be accomplish[ed] more safely by administering a lower dose of the drug than would be administered to a person who has normal CYP2D6 enzyme activity.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 2 ll. 15\u8211\'3f21. Nevertheless, the majority concludes that the claims here are not directed to ineligible subject matter at step one of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
/
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2033619398&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Alice
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 inquiry. Majority Op. at 28. I disagree.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The representative claim in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, i.e., Claim 1, recited:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A method of optimizing therapeutic efficacy for treatment of an immune-mediated 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Icac9cfe6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
gastrointestinal disorder
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, comprising:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(a) administering a drug providing 6-thioguanine to a subject having said immune-mediated 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Icac9cfe6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
gastrointestinal disorder
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
; and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
(b) determining the level of 6-thioguanine in said subject having said immune-mediated 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Icac9cfe6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
gastrointestinal disorder
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
wherein the level of 6-thioguanine less than about 230 pmol per 8x10
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
8
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 red blood cells indicates a need to increase the amount of said drug subsequently administered to said subject and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
wherein the level of 6-thioguanine greater than about 400 pmol per 8x10
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
8
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 red blood cells indicates a need to decrease 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1141_15}{\*\bkmkend co_pp_sp_506_1141_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1141
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 the amount of said drug subsequently administered to said subject.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_74&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_74" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 74\u8211\'3f75, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2002176446&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I175c6f3071fc11d7ab54daa4035d65fa&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
U.S. Patent No. 6,355,623
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 20 ll. 10\u8211\'3f20).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court stated that the patent in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 \u8220\'3fset forth laws of nature\u8212\'3fnamely, relationships between concentrations of certain metabolites in the blood and the likelihood that a dosage of a thiopurine drug will prove ineffective or cause harm.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 77, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. As one example of the laws of nature set forth in the patent, the Court pointed to Claim 1\rquote s statement \u8220\'3fthat 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
if
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the levels of 6-TG in the blood (of a patient who has taken a dose of a thiopurine drug) exceed about 400 pmol per 8x10
}
{\b0 \cf1 \f2 \i0 \fs16 
{\super \b0 \cf1 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
8
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 red blood cells, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
then
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the administered dose is likely to produce toxic side effects.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Thus, the law of nature identified by the Supreme Court in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 encompassed not only the bare fact of the relationship between thiopurine metabolite concentrations and efficacy or side effects of a thiopurine drug, but also the precise levels of concentration in question. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 74, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (\u8220\'3fBut those in the field did not know the precise correlations between metabolite levels and likely harm or ineffectiveness. The patent claims at issue here set forth processes embodying researchers\rquote  findings that identified these correlations with some precision.\u8221\'3f).
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
In the present case, Claim 1 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 reads as follows:
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
A method for treating a patient with iloperidone, wherein the patient is suffering from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
, the method comprising the steps of:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
determining whether the patient is a CYP2D6 poor metabolizer by:
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
obtaining or having obtained a biological sample from the patient;
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li400 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
performing or having performed a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=mproc&entityId=Ib3510dc6475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
genotyping
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
 assay on the biological sample to determine if the patient has a CYP2D6 poor metabolizer genotype; and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
if the patient has a CYP2D6 poor metabolizer genotype, then internally administering iloperidone to the patient in an amount of 12 mg/day or less, and
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
if the patient does not have a CYP2D6 poor metabolizer genotype, then internally administering iloperidone to the patient in an amount that is greater than 12 mg/day, up to 24 mg/day,
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li200 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb200 
wherein a risk of QTc prolongation for a patient having a CYP2D6 poor metabolizer genotype is lower following the internal administration of 12 mg/day or less than it would be if the iloperidone were administered in an amount of greater than 12 mg/day, up to 24 mg/day.
\par 
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 col. 17 ll. 2\u8211\'3f25.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
This claim, which is representative of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, also sets forth a natural relationship\u8212\'3fnamely, the relationship between the CYP2D6 genotype and the likelihood that a dosage of iloperidone will cause QTc prolongation. The majority notes that the claims in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 were directed to the relationships that comprised the natural law, and not \u8220\'3fto a novel method of treating a disease.\u8221\'3f Majority Op. at 29. Here, according to the majority, while the inventors 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
recognized
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 a natural law, \u8220\'3fthat is not what they claimed.\u8221\'3f 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 30. Rather, the claims of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 require a treating doctor to administer iloperidone in \u8220\'3fspecific dosages\u8221\'3f based on the results of a genotyping assay. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 But reciting specific metes and bounds in the claims did not prevent the Supreme Court from concluding those claims set forth a natural law in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. We are not free to depart from the Supreme Court\rquote s holding.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1142_15}{\*\bkmkend co_pp_sp_506_1142_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1142
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 As the majority notes, the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 claims a method of treating 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 with iloperidone \u8220\'3fthat is safer for patients because it reduces the risk of QTc prolongation.\u8221\'3f Majority Op. at 30. This is no more than an optimization of an existing treatment of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, just as the claims in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 concerned \u8220\'3foptimizing therapeutic efficacy\u8221\'3f of thiopurine drugs. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 warned against \u8220\'3fdrafting effort[s] designed to monopolize the law of nature itself.\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_77&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_77" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
566 U.S. at 77, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The majority does not heed that warning.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The Court in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 found that the claim limitation concerning \u8220\'3fadministering\u8221\'3f a thiopurine drug to a patient \u8220\'3fsimply refer[red] to the relevant audience, namely doctors who treat patients with certain diseases with thiopurine drugs\u8221\'3f\u8212\'3fan audience that existed long before the patent disclosure. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000708&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 78, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. So too here. The audience of physicians treating 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Ic8ad584c475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
schizophrenia
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 with iloperidone long predated the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\rquote 610 patent
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. The patent simply discloses the natural law that a known side effect of the existing treatment could be reduced by administering a lower dose to CYP2D6 poor-metabolizers. It claims no more than instructions directing that audience to apply the natural law in a routine and conventional manner.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The majority fails to reconcile this substantive similarity between our case and 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. Instead, it points to the specific dosages as a distinction between the administering step here and that in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. But 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 examined the significance of the \u8220\'3fadministering\u8221\'3f step in its search for an inventive concept, 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
not
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 as part of the determination whether the claims were directed to a natural law at the threshold. And the specific dosage adds nothing inventive to the claims beyond the natural law.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Nor does the other element of specificity identified by the majority rescue the claims. The claims here specify a means of identifying a patient\rquote s genotype (a \u8220\'3fgenetic assay\u8221\'3f), while the claims in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 left open the means of measuring the relevant metabolite. But the genetic assay is purely conventional pre-solution activity that cannot be used to circumvent eligibility under 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS101&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=LQ&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u167\'3f
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}
{\b1 \cf20 \f2 \i0 \fs20 \chcbpat26 
{\b1 \cf20 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
101
}
}
{\b0 \cf19 \f2 \i0 \fs20 \chcbpat2 
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_79&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_79" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 79, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The majority notes the claims here 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
require
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 treatment with iloperidone within the dosage range indicated, while the claims in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 could be infringed by treatment with thiopurine \u8220\'3f
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
whether that treatment does, or does not, change in light of the inference
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u8221\'3f indicated by the natural law. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_86&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_86" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 86, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (emphasis added); 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
see
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 Majority Op. at 30\u8211\'3f31. But that inquiry in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 also came as part of the search for an inventive concept, and requiring a dosage instead of indicating a dosage is not sufficient at step two. The difference is of no moment.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
The majority points to the Supreme Court\rquote s statement in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 that \u8220\'3f[u]nlike, say, a typical patent on a new drug or a new way of using an existing drug, the patent claims do not confine their reach to particular applications of those laws.\u8221\'3f Majority Op. at 29\u8211\'3f30 (quoting 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_780_87&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_780_87" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, 566 U.S. at 87, 132 S.Ct. 1289
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
). It similarly points to our decision in 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Rapid Litigation Management Ltd. v. CellzDirect, Inc.
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, wherein we indicated that \u8220\'3fthe natural ability of the subject matter to 
}
{\b0 \cf1 \f2 \i1 \fs20 
{\b0 \cf1 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
undergo
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 the process does not make the claim \u8216\'3fdirected to\u8217\'3f that natural ability,\u8221\'3f lest we find ineligible methods of \u8220\'3ftreating 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 with chemotherapy (as directed to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=disease&entityId=Iaf34f5c3475411db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
cancer
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 cells\rquote  inability to survive chemotherapy), or treating headaches with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af17fb7475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
aspirin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 (as directed to the human body\rquote s natural response to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?entityType=gdrug&entityId=I3af17fb7475111db9765f9243f53508a&originationContext=document&transitionType=DocumentItem&contextData=(sc.Default)&vr=3.0&rs=cblt1.0" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
aspirin
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
).\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1049&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1049" }{\fldrslt 
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
827 F.3d 1042, 1049 (Fed. Cir. 2016)
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. But that is not this case.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Whatever weight can be ascribed to the foregoing statements about methods of 
}
{\b1 \cf1 \f2 \i0 \fs20 
{\*\bkmkstart co_pp_sp_506_1143_15}{\*\bkmkend co_pp_sp_506_1143_15}
{\b1 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
*1143
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 treatment, we remain beholden to the holding of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, which, in my view, requires us to find the claims directed to a natural law at step one. (And I find no inventive concept in the claims once the natural law at issue is properly understood in view of 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.)
}
{\b0 \cf1 \f2 \i0 \fs16 
{\*\bkmkstart co_fnRef_B00102044320422_ID0E6HEK_15}{\*\bkmkend co_fnRef_B00102044320422_ID0E6HEK_15}
{\field {\*\fldinst HYPERLINK "#co_footnote_B00102044320422_15" }{\fldrslt 
{\super \b0 \cf19 \f2 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
1
}}}
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
My conclusion is not at odds with 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
CellzDirect
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
. There, the alleged law of nature was the capability of hepatocyte cells to survive multiple freeze-thaw cycles. Because the \u8220\'3fend result\u8221\'3f of the claims therein was \u8220\'3fnot simply an observation or detection of the ability of hepatocytes to survive multiple freeze-thaw cycles\u8221\'3f but rather \u8220\'3fa new and useful method of preserving hepatocyte cells,\u8221\'3f we held the claims were not directed to a law of nature. 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039315377&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1049&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1049" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Id.
}
}
{\b0 \cf19 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
 at 1049
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Here, the end result of the claimed process is no more than the conclusion of a natural law. The fact that a reduction of iloperidone dosage in poor metabolizers to the may reduce QTc prolongation is both the means and the ends of this claim. The recitation of the specific dosages adds no more than a conventional application of that natural law. I see no distinction from 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027337692&pubNum=0000780&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f2 \i1 \fs20 
{\b0 \cf19 \f2 \ul0 \strike0 \i1 \fs20 \sa0 \sb0 
Mayo
}
}}}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
, so I would hold the asserted claims directed to ineligible subject matter and lacking an inventive concept sufficient to transform it into patent-eligible subject matter. I respectfully dissent.
\par 
}
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
\u160\'3f
\par 
}
}
}
}
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
{\b1 \cf21 \f2 \ri0 \i0 \qj \fs20 \li0 
{\*\bkmkstart co_allCitations_15}{\*\bkmkend co_allCitations_15}
{\b1 \cf21 \f2 \ul0 \strike0 \i0 \fs20 \sa200 \sb200 
All Citations
\par 
}
}
{\b0 \cf1 \f2 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
887 F.3d 1117, 126 U.S.P.Q.2d 1266
\par 
}
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \ltrrow \trleft0 
\clpadl200 \clpadfl3 \clbrdrt \clbrdrl \trql \clwWidth10080 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs20 \li0 
{\b0 \cf1 \f4 \i0 \fs20 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs20 \sa0 \sb0 
Footnotes
\par 
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \ql \li0 \fs20 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00012044320422_15}{\*\bkmkend co_footnote_B00012044320422_15}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00012044320422_ID0EKDAI_15" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The parties have not appealed any determinations with respect to the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 198 patent
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. The parties stipulated to the infringement of claim 3 of the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2009579817&pubNum=0004073&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=Id04ab71917f711db9a6ba61a2ffc7828&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 198 patent
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 and the court concluded that claim 3 would not have been obvious.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00022044320422_15}{\*\bkmkend co_footnote_B00022044320422_15}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00022044320422_ID0ETGAI_15" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
2
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The QT interval is the time between the Q and T waves of the heart rhythm. When corrected for the patient\rquote s heart rate it is abbreviated QTc.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00032044320422_15}{\*\bkmkend co_footnote_B00032044320422_15}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00032044320422_ID0E6OAI_15" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
3
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
During the pendency of this appeal, ownership of ANDA 20-5480 transferred from Roxane Laboratories Inc. to West-Ward. For simplicity, we refer to the ANDA applicant throughout as West-Ward.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00042044320422_15}{\*\bkmkend co_footnote_B00042044320422_15}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00042044320422_ID0EUBBI_15" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
4
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
The court specifically stated that Vanda was \u8220\'3fnot entitled to relief pursuant to 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_f4aa000038542" }{\fldrslt 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat26 
{\b1 \cf20 \f4 \i0 \fs18 \chcbpat26 
{\b1 \cf20 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
35
}
}
}
{\b0 \cf19 \f4 \i0 \fs18 \chcbpat2 
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 U.S.C. \u167\'3f 271(e)(4)(A)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \chcbpat2 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 for the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 610
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 [p]atent because the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 610
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 [p]atent did not issue until after the effective date of any FDA approval of [West-Ward\rquote s] ANDA....\u8221\'3f 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2039653953&pubNum=0007903&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_7903_435&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_7903_435" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Opinion
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 203 F.Supp.3d at 435
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
. But the parties have treated the district court\rquote s reference to \u8220\'3fthe effective date of any FDA approval\u8221\'3f as a typographical error, and the district court\rquote s rationale as being based on the 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2032082448&pubNum=0004074&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=PA&docFamilyGuid=I1005687053b611e3abd5cd17c6ad87ba&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\rquote 610 patent
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 not having issued until after the filing date of the ANDA. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 Appellant Br. 28; Appellee Br. 60 & n.6. We do the same.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00052044320422_15}{\*\bkmkend co_footnote_B00052044320422_15}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00052044320422_ID0EW4BI_15" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
5
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Because we determine that 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=28USCAS1338&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_8b3b0000958a4" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
28 U.S.C. \u167\'3f 1338(a)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 provides a proper basis for jurisdiction, we do not reach the parties\rquote  declaratory judgment jurisdiction arguments.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00062044320422_15}{\*\bkmkend co_footnote_B00062044320422_15}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00062044320422_ID0EKWCI_15" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
6
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
We note that West-Ward did not argue to the district court at the pleadings stage that the complaint should be dismissed for failure to state a claim upon which relief could be granted on this basis. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
Cf. 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2027068440&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1381&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1381" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
AstraZeneca II
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 669 F.3d at 1381
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (concluding that \u8220\'3fthe district court erred in part by concluding that [patentee\rquote s] failure to state a cognizable 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f 271(e)(2)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 claim defeated its jurisdiction\u8221\'3f and affirming the dismissal for \u8220\'3ffail[ure] to state a 
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=L&pubNum=1000546&cite=35USCAS271&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RB&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_1184000067914" }{\fldrslt 
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
\u167\'3f 271(e)(2)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 claim\u8221\'3f where applicant moved to dismiss both for lack of jurisdiction and failure to state a claim).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00072044320422_15}{\*\bkmkend co_footnote_B00072044320422_15}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00072044320422_ID0ETIDI_15" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
7
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Because we conclude that the district court did not clearly err in finding induced infringement, we need not and do not reach Vanda\rquote s arguments in the alternative on contributory infringement.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00082044320422_15}{\*\bkmkend co_footnote_B00082044320422_15}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00082044320422_ID0EU5DI_15" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
8
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Because we affirm the district court\rquote s infringement findings with respect to these independent claims, we need not reach this issue regarding the dependent claims because any error in the district court\rquote s analysis of the dependent claims is harmless. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See 
}
}
{\field {\*\fldinst HYPERLINK "http://www.westlaw.com/Link/Document/FullText?findType=Y&serNum=2014959885&pubNum=0000506&originatingDoc=I7b55ac403f3c11e8a70fc9d8a0b2aef5&refType=RP&fi=co_pp_sp_506_1312&originationContext=document&vr=3.0&rs=cblt1.0&transitionType=DocumentItem&contextData=(sc.Search)#co_pp_sp_506_1312" }{\fldrslt 
{\b0 \cf19 \f4 \i1 \fs18 
{\b0 \cf19 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
TiVo, Inc. v. EchoStar Commc\rquote ns Corp.
}
}
{\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
, 516 F.3d 1290, 1312 (Fed. Cir. 2008)
}\b0 \cf19 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 }}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 (affirming infringement finding as to some but not all claims and explaining that \u8220\'3f[b]ecause the damages calculation at trial was not predicated on the infringement of particular claims, and because we have upheld the jury\rquote s verdict that all of the accused devices infringe the software claims, we affirm the damages award entered by the district court\u8221\'3f).
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \ltrrow \trleft0 
\clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00092044320422_15}{\*\bkmkend co_footnote_B00092044320422_15}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00092044320422_ID0ECCBK_15" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
9
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
For purposes of validity, the parties did not argue the claims separately, so they rise or fall together.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }
{\trowd \lastrow \trleft0 
\clbrdrb \clbrdrl \trql \clvertalt \clwWidth600 \cellx600 
\clbrdrb \clbrdrr \trql \clwWidth9480 \cellx10080 
\intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 
{\b0 \cf1 \f4 \i0 \fs24 
{\*\bkmkstart co_footnote_B00102044320422_15}{\*\bkmkend co_footnote_B00102044320422_15}
{\field {\*\fldinst HYPERLINK "#co_fnRef_B00102044320422_ID0E6HEK_15" }{\fldrslt 
{\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 
1
}\super \b0 \cf19 \f4 \ul0 \strike0 \i0 \fs24 \sa0 \sb0 }}
\par 
}
}
}\b0 \cf1 \f4 \ri0 \i0 \ql \li0 \fs24 \intbl \cell \intbl 
{\ri0 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ri0 \i0 \qj \fs18 \li0 
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
Indeed, the unpredictable results of clinical testing regarding the relationship among CYP2D6, iloperidone, and QTc prolongation formed the basis of the district court\rquote s finding of non-obviousness. 
}
{\b0 \cf1 \f4 \i1 \fs18 
{\b0 \cf1 \f4 \ul0 \strike0 \i1 \fs18 \sa0 \sb0 
See
}
}
{\b0 \cf1 \f4 \ul0 \strike0 \i0 \fs18 \sa0 \sb0 
 J.A. 13\u8211\'3f15. In particular, the district court pointed to West-Ward\rquote s evidence that \u8220\'3fit was unpredictable whether any dosage adjustment would be needed for CYP2D6 poor metabolizers, much less the amount of adjustment needed to achieve the pharmacokinetic profile seen in normal metabolizers.\u8221\'3f J.A. 14. That is, the district court found non-obviousness based on the revelation of the natural law underpinning the claims, not in any other aspect of the claims.
\par 
}
}
}
}
}\b0 \cf1 \f4 \ri0 \ul0 \strike0 \i0 \qj \li0 \fs18 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}
{\b0 \cf1 \f4 \ri0 \i0 \ql \fs24 \li0 \par}\sect\sbknone\pgncont\cols1{\ids0 {
{\trowd \lastrow \trleft0 
\clpadt24 \clpadft3 \clpadl100 \clpadfl3 \clpadr24 \clpadfr3 \clbrdrt \brdrcf22 \brdrw10 \brdrs \clbrdrb \clbrdrl \trql \clvertalt \clwWidth4320 \cellx4320 
\clpadt29 \clpadft3 \clpadl100 \clpadfl3 \clpadr29 \clpadfr3 \clbrdrt \brdrcf22 \brdrw10 \brdrs \clbrdrb \clbrdrr \trql \clvertalt \clwWidth5760 \cellx10080 
\intbl 
{\ri24 \li24 
{\b1 \cf22 \f4 \ri24 \i0 \ql \fs16 \li24 
{\b1 \cf22 \f4 \ul0 \strike0 \i0 \fs16 \sa0 \sb0 
End of Document
\par 
}
}
}\b1 \cf22 \f4 \ri24 \ul0 \strike0 \i0 \ql \li24 \fs16 \sa0 \sb0 \intbl \cell \intbl 
{\ri29 \li29 
{\qr \b0 \cf22 \f4 \ri29 \i0 \fs19 \li29 
{\b0 \cf22 \f4 \ul0 \strike0 \i0 \fs19 \sa0 \sb0 
\u169\'3f 2021 Thomson Reuters. No claim to original U.S. Government Works.
\par 
}
}
}\qr \b0 \cf22 \f4 \ri29 \ul0 \strike0 \i0 \li29 \fs19 \sa0 \sb0 \intbl \cell \row }}\par 
}
{\b0 \cf1 \f2 \ri0 \par}\sect\sbknone\pgncont\cols2{\ids0 \i0 \qj \fs20 \li0 
{\b0 \cf1 \f2 \ri0 \i0 \qj \fs20 \li0 
}
}\sect }